ORIGINAL RESEARCH original O OR ORI ORIG BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 1 0 0 1
Triple Combination triple T Tr Tri Trip BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 ./ 2 9 0 0 0 0 1
Adapalene 0.15%/Benzoyl adapalene A Ad Ada Adap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ./.: 4 9 0 0 0 0 1
Efficacy and efficacy E Ef Eff Effi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
Leon H. leon L Le Leo Leon BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 0 ...... 6 10 0 0 0 0 1
Julie C. julie J Ju Jul Juli BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 1 ...... 6 10 0 0 0 0 1
Neal Bhatia neal N Ne Nea Neal BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 1 ..... 5 10 0 0 0 0 1
Hilary Baldwin hilary H Hi Hil Hila BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 1 ..... 5 10 0 0 0 0 1
George Han george G Ge Geo Geor BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 1 ...... 6 10 0 0 0 0 1
Edward (Ted) edward E Ed Edw Edwa BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 2 (). 3 10 0 0 0 0 1
Received: February received: R Re Rec Rece BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 :,/:,/:, 8 10 0 0 0 0 1
Ó The ó Ó Ó Ó Ó BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 2 () 2 2 0 0 0 0 1
ABSTRACT ABSTRACT abstract A AB ABS ABST BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 10 0 0 0 0 1
Introduction: A introduction: I In Int Intr BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 3 :- 2 9 0 0 0 0 1
acne treatment acne a ac acn acne BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 , 1 8 0 0 0 0 1
antimicrobial, and antimicrobial, a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 ,- 2 10 0 0 0 0 1
cacious than cacious c ca cac caci BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 / 1 9 0 0 0 0 1
potentially reducing potentially p po pot pote BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 . 1 9 0 0 0 0 1
study evaluated study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 9 0 0 0 0 1
first fixed-dose, first f fi fir firs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 -,- 3 10 0 0 0 0 1
product, clindamycin product, p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ,././ 5 8 0 0 0 0 1
benzoyl peroxide benzoyl b be ben benz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 ().() 5 8 0 0 0 0 1
pooled phase pooled p po poo pool BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 . 1 4 0 0 0 0 1
Methods: In methods: M Me Met Meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 3 :(; 3 8 0 0 0 0 1
N = n N N N N BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 3 ),-,-,- 7 9 0 0 0 0 1
ticipants aged ticipants t ti tic tici BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 --- 3 9 0 0 0 0 1
ere acne ere e er ere ere BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 :- 2 9 0 0 0 0 1
daily CAB daily d da dai dail BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 3 . 1 9 0 0 0 0 1
C 2-grade c C C C C BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 3 -- 2 8 0 0 0 0 1
tor's Global tor's t to tor tor' BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 '/ 2 9 0 0 0 0 1
clear skin clear c cl cle clea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ()- 3 9 0 0 0 0 1
mean percent mean m me mea mean BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 8 0 0 0 0 1
lesion counts. lesion l le les lesi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 .- 2 8 0 0 0 0 1
events (TEAEs) events e ev eve even BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 3 ()/ 3 9 0 0 0 0 1
Prior Presentation: prior P Pr Pri Prio BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 6 : 1 10 0 0 0 0 1
analysis were analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 9 0 0 0 0 1
congresses: Maui congresses: c co con cong BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 :,- 3 10 0 0 0 0 1
Derm PA derm D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 , 1 8 0 0 0 0 1
Dermatology Conference dermatology D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 6 ,, 2 8 0 0 0 0 1
ODAC Dermatology, odac O OD ODA ODAC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 0 6 , 1 9 0 0 0 0 1
2024. 2024. 2024. 2 20 202 2024 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 6 . 1 1 0 0 0 0 1
Supplementary Information supplementary S Su Sup Supp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 7 no 0 8 0 0 0 0 1
contains supplementary contains c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 :// 3 10 0 0 0 0 1
doi.org/10.1007/s13555-024-01155-7. doi.org/10.1007/s13555-024-01155-7. doi.org/10.1007/s13555-024-01155-7. d do doi doi. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 7 ././---. 8 6 0 0 0 0 1
L. H. l. L L. L. L. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 ..() 4 3 0 0 0 0 1
Icahn School icahn I Ic Ica Icah BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 ,, 2 10 0 0 0 0 1
NY, USA ny, N NY NY, NY, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 , 1 1 0 0 0 0 1
e-mail: wedoderm@yahoo.com e-mail: e e- e-m e-ma BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 8 -:@. 4 5 0 0 0 0 1
L. H. l. L L. L. L. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 .. 2 3 0 0 0 0 1
Indiana University indiana I In Ind Indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 , 1 10 0 0 0 0 1
Indianapolis, IN, indianapolis, I In Ind Indi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 8 ,, 2 5 0 0 0 0 1
L. H. l. L L. L. L. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 .. 2 2 0 0 0 0 1
Physicians Skin physicians P Ph Phy Phys BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 ,, 2 10 0 0 0 0 1
#2310, Louisville, #2310, # #2 #23 #231 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 9 #,,, 4 7 0 0 0 0 1
L. H. l. L L. L. L. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 .. 2 3 0 1 0 0 1
DermResearch, PLLC, dermresearch, D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 9 ,,,, 4 10 0 1 0 0 1
L. H. l. L L. L. L. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 .. 2 3 0 0 0 0 1
Skin Sciences, skin S Sk Ski Skin BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 ,,,, 4 10 0 0 0 0 1
L. Stein l. L L. L. L. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 . 1 3 0 0 0 0 1
Henry Ford henry H He Hen Henr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 10 ,,, 3 10 0 0 0 0 1
M. Gold m. M M. M. M. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 . 1 1 0 0 0 0 1
Tennessee Clinical tennessee T Te Ten Tenn BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 ,,, 3 10 0 0 0 0 1
USA USA usa U US USA USA BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 no 0 0 0 0 0 0 1
J. S. j. J J. J. J. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 10 .. 2 2 0 0 0 0 1
Georgia Dermatology georgia G Ge Geo Geor BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 10 ,,, 3 10 0 0 0 0 1
J. S. j. J J. J. J. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 .. 2 2 0 1 0 0 1
Gwinnett Clinical gwinnett G Gw Gwi Gwin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 ,.,, 4 10 0 1 0 0 1
GA, USA ga, G GA GA, GA, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 , 1 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 11 ()():- 6 10 0 1 1 1 0
https://doi.org/10.1007/s13555-024-01155-7 https://doi.org/10.1007/s13555-024-01155-7 https://doi.org/10.1007/s13555-024-01155-7 h ht htt http BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 0 11 ://././--- 10 9 0 1 0 0 0
were evaluated. were w we wer were BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 3 0 0 0 0 1
Results: At results: R Re Res Resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 :,. 3 8 0 0 0 0 1
achieved treatment achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 8 0 0 0 0 1
22.6% with 22.6% 2 22 22. 22.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 .(.).- 6 9 0 0 0 0 1
ted in ted t te ted ted BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 0 0 [ 1 8 0 0 0 0 1
noninflammatory lesions noninflammatory n no non noni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 (. 2 8 0 0 0 0 1
and 73.0%, and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 .,),- 5 9 0 0 0 0 1
cantly greater cantly c ca can cant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 (..; 4 9 0 0 0 0 1
P \ p P P P P BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 0 .,).- 5 8 0 0 0 0 1
moderate severity, moderate m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,- 2 8 0 0 0 0 1
participants participants participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 2 0 0 0 0 1
discontinued discontinued discontinued d di dis disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 2 0 0 0 0 1
study/treatment study/treatment study/treatment s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 / 1 3 0 0 0 0 1
because of because b be bec beca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 .- 2 9 0 0 0 0 1
line in line l li lin line BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,,,, 4 10 0 0 0 0 1
stinging were stinging s st sti stin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 9 0 0 0 0 1
back to back b ba bac back BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 0 . 1 8 0 0 0 0 1
Conclusions: The conclusions: C Co Con Conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 :-,- 4 9 0 0 0 0 1
combination clindamycin combination c co com comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ./ 2 8 0 0 0 0 1
adapalene 0.15%/BPO adapalene a ad ada adap BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 ./. 3 9 0 0 0 0 1
and well and a an and and BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ,, 2 9 0 0 0 0 1
adults with adults a ad adu adul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 --. 3 9 0 0 0 0 1
participants achieved participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 / 1 9 0 0 0 0 1
12 weeks, 12 1 12 12 12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 0 3 , 1 9 0 0 0 0 1
studies of studies s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 . 1 8 0 0 0 0 1
Trial Registration: trial T Tr Tri Tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 3 :. 2 10 0 0 0 0 1
NCT04214639 and nct04214639 N NC NCT NCT0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 3 . 1 5 0 0 0 0 1
Keywords: Acne; keywords: K Ke Key Keyw BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 5 :;;; 4 10 0 0 0 0 1
Clinical Clinical clinical C Cl Cli Clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 5 no 0 2 0 0 0 0 1
trial; trial; trial; t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 5 ; 1 1 0 0 0 0 1
Combination Combination combination C Co Com Comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 5 no 0 2 0 0 0 0 1
treatment; treatment; treatment; t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 5 ; 1 2 0 0 0 0 1
Retinoid; Topical retinoid; R Re Ret Reti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 5 ; 1 4 0 0 0 0 1
J. C. j. J J. J. J. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 5 .. 2 2 0 0 0 0 1
Dermatology & dermatology D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 5 , 1 10 0 0 0 0 1
Birmingham, AL, birmingham, B Bi Bir Birm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 5 ,, 2 4 0 0 0 0 1
J. Q. j. J J. J. J. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 .. 2 3 0 0 0 0 1
JDR Dermatology jdr J JD JDR JDR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 /, 2 10 0 0 0 0 1
Las Vegas, las L La Las Las BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 ,, 2 4 0 0 0 0 1
J. Q. j. J J. J. J. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 .. 2 3 0 0 0 0 1
Advanced Dermatology advanced A Ad Adv Adva BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 6 , 1 10 0 0 0 0 1
Maitland, FL, maitland, M Ma Mai Mait BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 ,, 2 4 0 0 0 0 1
J. Q. j. J J. J. J. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 7 .. 2 3 0 0 0 0 1
Touro University touro T To Tou Tour BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 7 ,,, 3 10 0 0 0 0 1
C. G. c. C C. C. C. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 7 .. 2 2 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 7 no 0 8 0 0 0 0 1
Translational Biomedicine, translational T Tr Tra Tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 7 ,, 2 10 0 0 0 0 1
Haven, CT, haven, H Ha Hav Have BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 7 ,, 2 3 0 0 0 0 1
N. Bhatia n. N N. N. N. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 . 1 1 0 0 0 0 1
Therapeutics Clinical therapeutics T Th The Ther BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 ,,, 3 10 0 0 0 0 1
E. A. e. E E. E. E. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 .. 2 3 0 0 0 0 1
Center for center C Ce Cen Cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 8 , 1 10 0 0 0 0 1
Sacramento, CA, sacramento, S Sa Sac Sacr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 ,, 2 4 0 0 0 0 1
L. F. l. L L. L. L. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 .. 2 3 0 0 0 0 1
School of school S Sc Sch Scho BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 ,, 2 10 0 0 0 0 1
Diego, CA, diego, D Di Die Dieg BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 ,, 2 3 0 0 0 0 1
L. F. l. L L. L. L. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 .. 2 4 0 0 0 0 1
Rady Children's rady R Ra Rad Rady BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 ',,, 4 10 0 0 0 0 1
H. Baldwin h. H H. H. H. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 . 1 2 0 0 0 0 1
The Acne the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 ,, 2 10 0 0 0 0 1
NY, USA ny, N NY NY, NY, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 , 1 1 0 0 0 0 1
H. Baldwin h. H H. H. H. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 . 1 2 0 0 0 0 1
Robert Wood robert R Ro Rob Robe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 10 , 1 10 0 0 0 0 1
Brunswick, NJ, brunswick, B Br Bru Brun BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 ,, 2 4 0 0 0 0 1
Z. D. z. Z Z. Z. Z. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 .. 2 3 0 0 0 0 1
Dermatology Consulting dermatology D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 10 ,, 2 10 0 0 0 0 1
Point, NC, point, P Po Poi Poin BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 10 ,, 2 3 0 0 0 0 1
V. D. v. V V. V. V. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 .. 2 3 0 0 0 0 1
Callender Dermatology callender C Ca Cal Call BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 10 , 1 10 0 0 0 0 1
Glenn Dale, glenn G Gl Gle Glen BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 10 ,, 2 4 0 0 0 0 1
V. D. v. V V. V. V. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 .. 2 4 0 0 0 0 1
Howard University howard H Ho How Howa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 11 , 1 10 0 0 0 0 1
Washington, DC, washington, W Wa Was Wash BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 ,, 2 5 0 0 0 0 1
1212 1212 1212 1 12 121 1212 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 1 11 no 0 1 0 1 0 0 0
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 ()():- 6 10 0 1 1 0 0
Key Summary key K Ke Key Key BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 0 no 0 10 0 1 0 0 1
Why carry why W Wh Why Why BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 ? 1 10 0 1 0 0 1
A three-pronged a A A A A BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 1 0 - 1 8 0 0 0 0 1
treatment using treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 7 0 0 0 0 1
antimicrobial, and antimicrobial, a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 , 1 10 0 0 0 0 1
easy-to-use topical easy-to-use e ea eas easy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 -- 2 9 0 0 0 0 1
improve efficacy improve i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 7 0 0 0 0 1
adherence. adherence. adherence. a ad adh adhe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 2 0 0 0 0 1
CAB polymeric cab C CA CAB CAB BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 ( 1 8 0 0 0 0 1
phosphate 1.2%/adapalene phosphate p ph pho phos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ././ 4 7 0 0 0 0 1
benzoyl peroxide benzoyl b be ben benz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 .)-- 4 9 0 0 0 0 1
dose triple-combination dose d do dos dose BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 8 0 0 0 0 1
product-demonstrated superior product-demonstrated p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
to vehicle to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 8 0 0 0 0 1
good safety/tolerability good g go goo good BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 0 / 1 10 0 0 0 0 1
two phase two t tw two two BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -- 2 10 0 0 0 0 1
acne. acne. acne. a ac acn acne BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 1 0 0 0 0 1
This post this T Th Thi This BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 10 0 0 0 0 1
the efficacy the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 10 0 0 0 0 1
pooled phase pooled p po poo pool BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 . 1 5 0 0 0 0 1
What was what W Wh Wha What BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 2 ? 1 10 0 1 0 0 1
Results from results R Re Res Resu BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 2 no 0 10 0 0 0 0 1
pooled randomized, pooled p po poo pool BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 ,-, 3 7 0 0 0 0 1
vehicle-controlled clinical vehicle-controlled v ve veh vehi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 - 1 9 0 0 0 0 1
participants with participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 -- 2 9 0 0 0 0 1
showed that showed s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 9 0 0 0 0 1
with CAB with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 9 0 0 0 0 1
by week by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 ,[ 2 8 0 0 0 0 1
inflammatory and inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 no 0 7 0 0 0 0 1
lesions. lesions. lesions. l le les lesi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 . 1 2 0 0 0 0 1
To our to T To To To BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 , 1 8 0 0 0 0 1
improvements in improvements i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 10 0 0 0 0 1
were greater were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 - 1 8 0 0 0 0 1
topical acne topical t to top topi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 , 1 10 0 0 0 0 1
CAB an cab C CA CAB CAB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 9 0 0 0 0 1
children, adolescents, children, c ch chi chil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 ,, 2 10 0 0 0 0 1
moderate-to-severe acne. moderate-to-severe m mo mod mode BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 --. 3 6 0 0 0 0 1
INTRODUCTION INTRODUCTION introduction I IN INT INTR BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 10 0 0 0 0 1
Acne vulgaris acne A Ac Acn Acne BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 8 0 0 0 0 1
logic disorder, logic l lo log logi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 , 1 10 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 4 []. 3 9 0 0 0 0 1
multifactorial, and multifactorial, m mu mul mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ,- 2 9 0 0 0 0 1
mation and mation m ma mat mati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ,- 2 8 0 0 0 0 1
liferation of liferation l li lif life BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ( 1 8 0 0 0 0 1
Propionibacterium acnes), propionibacterium P Pr Pro Prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 ),- 3 8 0 0 0 0 1
tinization [2, tinization t ti tin tini BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 [,].,- 6 9 0 0 0 0 1
ments that ments m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
pathological mechanisms pathological p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
efficacy compared efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 [].- 4 8 0 0 0 0 1
thermore, combination thermore, t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 , 1 8 0 0 0 0 1
delivered in delivered d de del deli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 8 0 0 0 0 1
improve patient improve i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 ,- 2 9 0 0 0 0 1
ment success, ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ,- 2 8 0 0 0 0 1
ity [5]. ity i it ity ity BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 []. 3 1 0 0 0 0 1
The most the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
guidelines in guidelines g gu gui guid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 8 0 0 0 0 1
combination treatment combination c co com comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 [,]. 4 9 0 0 0 0 1
Several topical several S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 - 1 9 0 0 0 0 1
products currently products p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 9 0 0 0 0 1
an antibiotic an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 4 no 0 9 0 0 0 0 1
benzoyl peroxide benzoyl b be ben benz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ().- 4 8 0 0 0 0 1
phate 1.2%/adapalene phate p ph pha phat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ././. 5 8 0 0 0 0 1
(CAB; Cabtreo (cab; ( (C (CA (CAB BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 (;;) 4 9 0 0 0 0 1
G. Han g. G G. G. G. BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 . 1 1 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 , 1 9 0 0 0 0 1
Zucker School zucker Z Zu Zuc Zuck BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 8 /, 2 10 0 0 0 0 1
New Hyde new N Ne New New BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 ,,, 3 6 0 0 0 0 1
M. J. m. M M. M. M. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 .. 2 3 0 0 0 0 1
Queens University, queens Q Qu Que Quee BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 ,,, 3 10 0 0 0 0 1
M. J. m. M M. M. M. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 .. 2 3 0 0 0 0 1
SKiN Centre skin S SK SKi SKiN BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 no 0 10 0 0 0 0 1
Research, Peterborough, research, R Re Res Rese BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 ,,, 3 7 0 0 0 0 1
N. Sadick n. N N. N. N. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 . 1 2 0 0 0 0 1
Weill Cornell weill W We Wei Weil BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 ,,, 3 10 0 0 0 0 1
N. Sadick n. N N. N. N. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 . 1 2 0 0 0 0 1
Sadick Dermatology, sadick S Sa Sad Sadi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 ,,, 3 10 0 0 0 0 1
M. P. m. M M. M. M. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 .. 2 2 0 0 0 0 1
Lupo Center lupo L Lu Lup Lupo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 no 0 10 0 0 0 0 1
Dermatology, New dermatology, D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 10 ,,, 3 8 0 0 0 0 1
Edward (Ted)Lain edward E Ed Edw Edwa BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 10 () 2 3 0 0 0 0 1
Austin Institute austin A Au Aus Aust BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 10 ,,, 3 10 0 0 0 0 1
USA USA usa U US USA USA BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 no 0 0 0 0 0 0 1
W. P. w. W W. W. W. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 .. 2 3 0 1 0 0 1
Elson S. elson E El Els Elso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 11 ., 2 10 0 1 0 0 1
State University, state S St Sta Stat BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 ,,, 3 7 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 ()():- 6 10 0 1 1 0 0
1213 1213 1213 1 12 121 1213 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 1 11 no 0 1 0 1 0 0 0
first triple-combination, first f fi fir firs BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -,- 3 10 0 0 0 0 1
treatment approved treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
Administration (FDA), administration A Ad Adm Admi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 0 (), 3 9 0 0 0 0 1
in patients in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 0 []. 3 9 0 0 0 0 1
addition to addition a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
phosphate has phosphate p ph pho phos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
skin [8, skin s sk ski skin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 [,],- 5 9 0 0 0 0 1
synthetic retinoid, synthetic s sy syn synt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,- 2 9 0 0 0 0 1
tion, tion, tion, t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 , 1 1 0 0 0 0 1
differentiation, differentiation, differentiation, d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 3 0 0 0 0 1
and and and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 0 0 0 0 0 1
keratinization keratinization keratinization k ke ker kera BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 3 0 0 0 0 1
[10, 11]. [10, [ [1 [10 [10, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 0 [,].,- 6 9 0 0 0 0 1
ucts, is ucts, u uc uct ucts BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 , 1 8 0 0 0 0 1
comedolytic and comedolytic c co com come BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 [,]. 4 9 0 0 0 0 1
Importantly, combining importantly, I Im Imp Impo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
clindamycin with clindamycin c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
reducing the reducing r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,- 2 9 0 0 0 0 1
cially during cially c ci cia cial BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 [], 3 9 0 0 0 0 1
goal of goal g go goa goal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
the Centers the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
entific Panel entific e en ent enti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
[14-16]. Overall, [14-16]. [ [1 [14 [14- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 0 [-]., 5 8 0 0 0 0 1
enhanced by enhanced e en enh enha BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
dients with dients d di die dien BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
that simultaneously that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
pathophysiological pathways pathophysiological p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 (.). 4 7 0 0 0 0 1
In a in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
moderate-to-severe acne, moderate-to-severe m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 --,- 4 9 0 0 0 0 1
with CAB with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
cantly greater cantly c ca can cant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
cle gel cle c cl cle cle BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 (/ 2 8 0 0 0 0 1
adapalene, clindamycin adapalene, a ad ada adap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 ,/, 3 8 0 0 0 0 1
clindamycin phosphate/adapalene) clindamycin c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 /)[]. 5 9 0 0 0 0 1
identical phase identical i id ide iden BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,,-, 4 9 0 0 0 0 1
vehicle-controlled trials, vehicle-controlled v ve veh vehi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -, 2 8 0 0 0 0 1
treatment led treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
centage of centage c ce cen cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
and significantly and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
matory and matory m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
with vehicle with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 [].- 4 10 0 0 0 0 1
ies, acne ies, i ie ies ies, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 ,[ 2 8 0 0 0 0 1
approximately 50% approximately a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
achieved treatment achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ., 2 9 0 0 0 0 1
data from data d da dat data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
more robustly more m mo mor more BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
life impacts, life l li lif life BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,, 2 10 0 0 0 0 1
in participants in i in in in BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 0 --. 3 9 0 0 0 0 1
METHODS METHODS methods M ME MET METH BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 10 0 1 0 0 1
Study Design study S St Stu Stud BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 10 0 1 0 0 1
A detailed a A A A A BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
methods of methods m me met meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 7 0 0 0 0 1
(NCT04214639 and (nct04214639 ( (N (NC (NCT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 2 6 () 2 7 0 0 0 0 1
published previously published p pu pub publ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 [].,- 5 10 0 0 0 0 1
ticipants were ticipants t ti tic tici BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 - 1 9 0 0 0 0 1
erate or erate e er era erat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 (' 2 9 0 0 0 0 1
Severity Score severity S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 6 [], 3 10 0 0 0 0 1
Electronic Supplementary electronic E El Ele Elec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 6 ), 2 8 0 0 0 0 1
B 100 b B B B B BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 2 6 no 0 1 0 0 0 0 1
inflammatory inflammatory inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 no 0 2 0 0 0 0 1
facial facial facial f fa fac faci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 1 0 0 0 0 1
lesions lesions lesions l le les lesi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 no 0 1 0 0 0 0 1
(papules/pustules/nodules), C (papules/pustules/nodules), ( (p (pa (pap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 (//), 5 8 0 0 0 0 1
noninflammatory facial noninflammatory n no non noni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 (/ 2 8 0 0 0 0 1
comedones), and comedones), c co com come BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 ),.- 4 8 0 0 0 0 1
pants were pants p pa pan pant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 : 1 9 0 0 0 0 1
of once-daily of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 -. 2 9 0 0 0 0 1
skin moisturization, skin s sk ski skin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 ,,, 3 9 0 0 0 0 1
CeraVeÒ hydrating ceraveò C Ce Cer Cera BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 6 (',, 4 9 0 0 0 0 1
NY), CeraVeÒ ny), N NY NY) NY), BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 6 ),,- 4 8 0 0 0 0 1
screen were screen s sc scr scre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 . 1 6 0 0 0 0 1
These studies these T Th The Thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
with principles with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 () 2 9 0 0 0 0 1
and the and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 . 1 9 0 0 0 0 1
across all across a ac acr acro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
same central same s sa sam same BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 8 0 0 0 0 1
(Advarra IRB, (advarra ( (A (Ad (Adv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 (,,,).- 7 9 0 0 0 0 1
pants or pants p pa pan pant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
informed consent informed i in inf info BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
trial from trial t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 6 .- 2 9 0 0 0 0 1
tional informed tional t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
individual participants individual i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
information/photographs are information/photographs i in inf info BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 / 1 9 0 0 0 0 1
article. article. article. a ar art arti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 . 1 1 0 0 0 0 1
Efficacy and efficacy E Ef Eff Effi BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 10 no 0 10 0 0 0 0 1
Participants were participants P Pa Par Part BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 10 ,, 2 10 0 0 0 0 1
and weeks and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 ,,,. 4 9 0 0 0 0 1
included facial included i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 - 1 8 0 0 0 0 1
matory lesion matory m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 10 , 1 8 0 0 0 0 1
defined as defined d de def defi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 no 0 8 0 0 0 0 1
achieving a achieving a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 - 1 9 0 0 0 0 1
in facial in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 10 ( 1 9 0 0 0 0 1
almost clear, almost a al alm almo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 , 1 8 0 0 0 0 1
Supplementary Material). supplementary S Su Sup Supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 10 ). 2 8 0 0 0 0 1
week 12, week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 ,- 2 8 0 0 0 0 1
Specific Specific specific S Sp Spe Spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 10 no 0 1 0 0 0 0 1
Quality Quality quality Q Qu Qua Qual BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 10 no 0 1 0 0 0 0 1
of of of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 10 no 0 0 0 0 0 0 1
Life Life life L Li Lif Life BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 10 no 0 0 0 0 0 0 1
(Acne-QoL) (Acne-QoL) (acne-qol) ( (A (Ac (Acn BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 10 (-) 3 2 0 0 0 0 1
1214 1214 1214 1 12 121 1214 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 2 11 no 0 1 0 1 0 0 0
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 11 ()():- 6 10 0 1 1 0 0
questionnaire, which questionnaire, q qu que ques BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 ,:- 3 9 1 0 0 0 1
perception, role-emotional, perception, p pe per perc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 ,-,-, 5 8 1 0 0 0 1
acne symptoms. acne a ac acn acne BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 . 1 8 1 0 0 0 1
are scored are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 ()(); 5 10 1 0 0 0 1
increase in increase i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 1 0 0 0 1
an improvement an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 0 - 1 9 1 0 0 0 1
[19]. [19]. [19]. [ [1 [19 [19] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 []. 3 1 1 0 0 0 1
Investigator assessments investigator I In Inv Inve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 8 1 0 0 0 1
(scaling, erythema, (scaling, ( (s (sc (sca BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 (,,,- 5 8 1 0 0 0 1
pigmentation) and pigmentation) p pi pig pigm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ) 1 8 1 0 0 0 1
tolerability (itching, tolerability t to tol tole BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 (,,) 4 9 1 0 0 0 1
face were face f fa fac face BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 9 1 0 0 0 1
using a using u us usi usin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -(,, 4 8 1 0 0 0 1
2 = 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 2 0 ,).() 5 9 1 0 0 0 1
were monitored were w we wer were BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 . 1 7 1 0 0 0 1
Statistical Analysis statistical S St Sta Stat BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 2 no 0 10 0 0 0 0 1
The intent-to-treat the T Th The The BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 2 --() 4 10 0 0 0 0 1
randomized participants randomized r ra ran rand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 . 1 9 0 0 0 0 1
participants who participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 no 0 9 0 0 0 0 1
the study the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 no 0 9 0 0 0 0 1
the safety the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 .,-- 4 9 0 0 0 0 1
mary endpoints mary m ma mar mary BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 2 2 no 0 9 0 0 0 0 1
participants achieving participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 no 0 8 0 0 0 0 1
week 12 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 no 0 9 0 0 0 0 1
week 12 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 no 0 8 0 0 0 0 1
lesion counts. lesion l le les lesi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 . 1 8 0 0 0 0 1
least-squares mean least-squares l le lea leas BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 - 1 8 1 0 0 0 1
counts from counts c co cou coun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 4 ,,, 3 9 1 0 0 0 1
the percentage the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 - 1 8 1 0 0 0 1
grade reduction grade g gr gra grad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 8 1 0 0 0 1
week 12. week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 . 1 1 1 0 0 0 1
Percent change percent P Pe Per Perc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 4 - 1 8 1 0 0 0 1
tory and tory t to tor tory BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 3 4 no 0 8 1 0 0 0 1
analyzed analyzed analyzed a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 1 1 0 0 0 1
using using using u us usi usin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 1 1 0 0 0 1
analysis analysis analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 1 1 0 0 0 1
of of of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 0 1 0 0 0 1
covariance covariance covariance c co cov cova BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 no 0 2 1 0 0 0 1
(ANCOVA), with (ancova), ( (A (AN (ANC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 4 (), 3 9 1 0 0 0 1
analysis center analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 8 1 0 0 0 1
lesion count lesion l le les lesi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 ; 1 9 1 0 0 0 1
skewness was skewness s sk ske skew BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 , 1 7 1 0 0 0 1
method was method m me met meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 8 1 0 0 0 1
transformed prior transformed t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 . 1 9 1 0 0 0 1
was analyzed was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
(using Firth's (using ( (u (us (usi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 (') 3 9 1 0 0 0 1
of treatment of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 . 1 8 1 0 0 0 1
Acne-QoL questionnaire acne-qol A Ac Acn Acne BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 4 -, 2 8 1 0 0 0 1
scores were scores s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 -- 2 9 1 0 0 0 1
to ANCOVA to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 8 1 0 0 0 1
and analysis and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 , 1 9 1 0 0 0 1
domain score domain d do dom doma BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 . 1 9 1 0 0 0 1
assessments except assessments a as ass asse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 -,- 3 8 1 0 0 0 1
tation was tation t ta tat tati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
the Markov the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 . 1 8 1 0 0 0 1
statistical analyses statistical s st sta stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
version 9.4 version v ve ver vers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 .. 2 10 1 0 0 0 1
based on based b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 - 1 9 1 0 0 0 1
resulting in resulting r re res resu BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 .. 2 4 1 0 0 0 1
Fig. 1 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 9 .- 2 9 1 0 0 0 1
combination CAB combination c co com comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 9 . 1 8 1 0 0 0 1
address three address a ad add addr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 9 : 1 9 1 0 0 0 1
adapalene normalizes adapalene a ad ada adap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 9 ;- 2 9 1 0 0 0 1
damycin and damycin d da dam damy BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 9 .; 2 10 1 0 0 0 1
three active three t th thr thre BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 -. 2 10 1 0 0 0 1
Image Ó2023. image I Im Ima Imag BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 .. 2 8 1 0 0 0 1
benzoyl peroxide, benzoyl b be ben benz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 ,./ 3 8 1 0 0 0 1
adapalene 0.15%/benzoyl adapalene a ad ada adap BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 ./. 3 6 1 0 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 11 ()():- 6 10 1 1 1 0 0
1215 1215 1215 1 12 121 1215 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 3 11 no 0 1 1 1 0 0 0
Additionally, co-primary additionally, A Ad Add Addi BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 ,-- 3 8 1 0 0 0 1
ondary endpoints ondary o on ond onda BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 (- 2 8 1 0 0 0 1
matory and matory m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ; 1 8 1 0 0 0 1
reduction of reduction r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ) 1 8 1 0 0 0 1
week 12 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 8 1 0 0 0 1
participants aged participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 -. 2 10 1 0 0 0 1
chosen to chosen c ch cho chos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 - 1 9 1 0 0 0 1
lescent participants, lescent l le les lesc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 , 1 9 1 0 0 0 1
than 25 than t th tha than BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 '''' 4 9 1 0 0 0 1
acne [20, acne a ac acn acne BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 [,]. 4 3 1 0 0 0 1
Cutaneous safety cutaneous C Cu Cut Cuta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 - 1 8 1 0 0 0 1
ments and ments m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 no 0 7 1 0 0 0 1
descriptive statistics. descriptive d de des desc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 . 1 9 1 0 0 0 1
Regulatory Activities regulatory R Re Reg Regu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 () 2 9 1 0 0 0 1
used to used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 . 1 9 1 0 0 0 1
for missing for f fo for for BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 . 1 5 1 0 0 0 1
RESULTS RESULTS results R RE RES RESU BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 3 4 no 0 10 0 1 0 0 1
Participant Disposition participant P Pa Par Part BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 10 0 1 0 0 1
A total a A A A A BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
CAB or cab C CA CAB CAB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 3 4 (.); 4 10 1 0 0 0 1
participants were participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
safety populations. safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 . 1 8 1 0 0 0 1
for study for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 8 1 0 0 0 1
request and request r re req requ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 -. 2 6 1 0 0 0 1
Demographics and demographics D De Dem Demo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 4 - 1 8 1 0 0 0 1
teristics are teristics t te ter teri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 . 1 9 1 0 0 0 1
similar for similar s si sim simi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 (- 2 9 1 0 0 0 1
proximately 20 proximately p pr pro prox BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 4 ), 2 9 1 0 0 0 1
aged \ aged a ag age aged BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 . 1 9 1 0 0 0 1
(58.4%), White (58.4%), ( (5 (58 (58. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 4 (.),(.), 8 9 1 0 0 0 1
at baseline at a at at at BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 (.). 4 4 1 0 0 0 1
Fig. 2 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 8 .. 2 9 1 0 0 0 1
participants were participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 8 no 0 9 1 0 0 0 1
two trials; two t tw two two BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 8 ; 1 10 1 0 0 0 1
and safety and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 8 ./. 3 10 1 0 0 0 1
b b b b b b b BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 3 10 no 0 10 1 0 0 0 1
Includes discontinuation includes I In Inc Incl BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 -, 2 8 1 0 0 0 1
lack of lack l la lac lack BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ,. 2 10 1 0 0 0 1
phosphate 1.2%/adapalene phosphate p ph pho phos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ././., 6 9 1 0 0 0 1
ITT intent itt I IT ITT ITT BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 10 no 0 3 1 0 0 0 1
1216 1216 1216 1 12 121 1216 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 3 11 no 0 1 0 1 0 0 0
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 11 ()():- 6 10 0 1 1 0 0
Efficacy and efficacy E Ef Eff Effi BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 10 0 0 0 0 1
At week at A At At At BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 , 1 9 0 0 0 0 1
all efficacy all a al all all BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (., 3 10 0 0 0 0 1
the Electronic the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ). 2 9 0 0 0 0 1
participants treated participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 - 1 9 0 0 0 0 1
ment success ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ,. 2 9 0 0 0 0 1
of participants of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 (.). 4 10 0 0 0 0 1
Mean absolute mean M Me Mea Mean BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 9 0 0 0 0 1
noninflammatory lesions noninflammatory n no non noni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 no 0 8 0 0 0 0 1
significantly greater significantly s si sig sign BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 9 0 0 0 0 1
(inflammatory, 29.0 (inflammatory, ( (i (in (inf BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 1 (,..;, 6 9 0 0 0 0 1
35.3 vs 35.3 3 35 35. 35.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 1 ..;.,).- 8 9 0 0 0 0 1
mean percent mean m me mea mean BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 - 1 9 0 0 0 0 1
matory and matory m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 1 no 0 8 0 0 0 0 1
were also were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 9 0 0 0 0 1
vehicle gel vehicle v ve veh vehi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 (.,), 5 9 0 0 0 0 1
with reductions with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 [ 1 8 0 0 0 0 1
treatment by treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 (.). 4 9 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 1 -, 2 9 0 0 0 0 1
rates and rates r ra rat rate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 9 0 0 0 0 1
to the to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 ( 1 8 0 0 0 0 1
Table S3 table T Ta Tab Tabl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 8 0 0 0 0 1
Material). Representative material). M Ma Mat Mate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 1 ). 2 9 0 0 0 0 1
improvements in improvements i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 9 0 0 0 0 1
are shown are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 .. 2 4 0 0 0 0 1
For all for F Fo For For BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 1 -,- 3 8 0 0 0 0 1
squares mean squares s sq squ squa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 () 2 8 0 0 0 0 1
baseline at baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 1 no 0 9 0 0 0 0 1
with CAB with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 (, 2 7 0 0 0 0 1
5.2-8.9, vehicle 5.2-8.9, 5 5. 5.2 5.2- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 1 .-.,.-.;.,;., 13 10 0 0 0 0 1
see Table see s se see see BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 1 no 0 9 0 0 0 0 1
Material). Material). material). M Ma Mat Mate BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 1 ). 2 2 0 0 0 0 1
Safety and safety S Sa Saf Safe BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 10 0 0 0 0 1
Treatment-emergent adverse treatment-emergent T Tr Tre Trea BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 -() 3 8 0 0 0 0 1
were generally were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 8 0 0 0 0 1
common among common c co com comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 8 0 0 0 0 1
(Table 2). (table ( (T (Ta (Tab BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ().- 4 9 0 0 0 0 1
TEAEs (C teaes T TE TEA TEAE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 4 () 2 9 0 0 0 0 1
erythema and erythema e er ery eryt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ,, 2 9 0 0 0 0 1
and irritation and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ( 1 9 0 0 0 0 1
Supplementary Material). supplementary S Su Sup Supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 ). 2 9 0 0 0 0 1
reported in reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 .- 2 9 0 0 0 0 1
tions due tions t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 - 1 9 0 0 0 0 1
participants (\ participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 (). 3 4 0 0 0 0 1
Transient increases transient T Tr Tra Tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 - 1 9 0 0 0 0 1
gator-assessed scaling gator-assessed g ga gat gato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 -- 2 8 0 0 0 0 1
ticipant-assessed itching, ticipant-assessed t ti tic tici BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 -,, 3 9 0 0 0 0 1
occurred with occurred o oc occ occu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 . 1 9 0 0 0 0 1
these measures these t th the thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 (.), 4 9 0 0 0 0 1
with substantial with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 ,- 2 9 0 0 0 0 1
lution back lution l lu lut luti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 . 1 10 0 0 0 0 1
Additionally, erythema additionally, A Ad Add Addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 ,- 2 8 0 0 0 0 1
baseline levels baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 (:, 3 10 0 0 0 0 1
0.57; week 0.57; 0 0. 0.5 0.57 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 .;,.).- 7 9 0 0 0 0 1
assessed hyperpigmentation assessed a as ass asse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 - 1 8 0 0 0 0 1
tation were tation t ta tat tati BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 . 1 9 0 0 0 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 10 0 1 0 0 1
(ITT population) (itt ( (I (IT (ITT BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 () 2 3 0 1 0 0 1
CAB gel cab C CA CAB CAB BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 8 0 1 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 () 2 10 0 1 0 0 1
Vehicle gel vehicle V Ve Veh Vehi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 10 0 1 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 () 2 8 0 1 0 0 1
Age, mean age, A Ag Age Age, BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 ,(), 4 9 0 1 0 0 1
20.2 (7.29) 20.2 2 20 20. 20.2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 7 .(.).(.) 8 10 0 1 0 0 1
Age, median age, A Ag Age Age, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 ,(),(-)(-) 10 10 0 0 0 0 1
Female, n female, F Fe Fem Fema BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 ,() 3 10 0 0 0 0 1
144 (59.5) 144 1 14 144 144 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 7 0 0 0 0 1
68 (56.2) 68 6 68 68 68 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 7 0 0 0 0 1
Ethnicity, Ethnicity, ethnicity, E Et Eth Ethn BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 , 1 4 0 0 0 0 1
Hispanic/Latino, n hispanic/latino, H Hi His Hisp BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 /,() 4 10 0 0 0 0 1
57 (23.6) 57 5 57 57 57 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
23 (19.0) 23 2 23 23 23 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
Race, n race, R Ra Rac Race BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 ,() 3 10 0 0 0 0 1
White White white W Wh Whi Whit BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 9 no 0 5 0 0 0 0 1
169 (69.8) 169 1 16 169 169 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 10 0 0 0 0 1
98 (81.0) 98 9 98 98 98 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 9 0 0 0 0 1
Black Black black B Bl Bla Blac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 9 no 0 6 0 0 0 0 1
40 (16.5) 40 4 40 40 40 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 10 0 0 0 0 1
14 (11.6) 14 1 14 14 14 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 10 0 0 0 0 1
Asian Asian asian A As Asi Asia BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 no 0 6 0 0 0 0 1
21 (8.7) 21 2 21 21 21 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 10 0 0 0 0 1
5 (4.1) 5 5 5 5 5 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 9 (.) 3 8 0 0 0 0 1
Other a other O Ot Oth Othe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 no 0 8 0 0 0 0 1
12 (5.0) 12 1 12 12 12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 10 0 0 0 0 1
4 (3.3) 4 4 4 4 4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 9 (.) 3 8 0 0 0 0 1
Inflammatory lesion inflammatory I In Inf Infl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 , 1 10 0 0 0 0 1
mean (SD) mean m me mea mean BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 () 2 3 0 0 0 0 1
36.9 (7.73) 36.9 3 36 36. 36.9 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 .(.).(.) 8 10 0 0 0 0 1
Noninflammatory lesion noninflammatory N No Non Noni BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
count, mean count, c co cou coun BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 10 ,() 3 7 0 0 0 0 1
49.4 (17.32) 49.4 4 49 49. 49.4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 .(.).(.) 8 10 0 0 0 0 1
Evaluator's Global evaluator's E Ev Eva Eval BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 ',() 4 10 0 0 0 0 1
3, moderate 3, 3 3, 3, 3, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 , 1 10 0 0 0 0 1
216 (89.3) 216 2 21 216 216 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 10 (.) 3 9 0 0 0 0 1
115 (95.0) 115 1 11 115 115 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 10 (.) 3 9 0 0 0 0 1
4, severe 4, 4 4, 4, 4, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 , 1 10 0 0 0 0 1
26 (10.7) 26 2 26 26 26 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 10 (.) 3 10 0 0 0 0 1
6 (5.0) 6 6 6 6 6 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 10 (.) 3 8 0 0 0 0 1
CAB clindamycin cab C CA CAB CAB BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 ././- 5 9 0 0 0 0 1
zoyl peroxide zoyl z zo zoy zoyl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 11 .,, 3 10 0 0 0 0 1
deviation deviation deviation d de dev devi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 11 no 0 1 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 4 11 no 0 10 0 0 0 0 1
Includes race includes I In Inc Incl BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 /, 2 10 0 0 0 0 1
Other Pacific other O Ot Oth Othe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 , 1 9 0 0 0 0 1
Native Native native N Na Nat Nati BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 no 0 1 0 0 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 11 ()():- 6 10 0 1 1 0 0
1217 1217 1217 1 12 121 1217 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 11 no 0 1 0 1 0 0 0
DISCUSSION DISCUSSION discussion D DI DIS DISC BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 1 0 0 0 1
This post this T Th Thi This BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 0 0 0 0 1
identical phase identical i id ide iden BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 , 1 10 0 0 0 0 1
safety, and safety, s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,- 2 8 0 0 0 0 1
approved, innovative approved, a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,-,-- 5 9 0 0 0 0 1
nation clindamycin nation n na nat nati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 0 ./ 2 8 0 0 0 0 1
0.15%/BPO 3.1% 0.15%/bpo 0 0. 0.1 0.15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 ./.- 4 8 0 0 0 0 1
moderate-to-severe acne. moderate-to-severe m mo mod mode BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 --. 3 7 0 0 0 0 1
vehicle gel, vehicle v ve veh vehi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 , 1 10 1 0 0 0 1
on all on o on on on BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 - 1 9 1 0 0 0 1
tolerated. Half tolerated. t to tol tole BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 .- 2 9 1 0 0 0 1
achieved treatment achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 . 1 8 1 0 0 0 1
addition, CAB addition, a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 2 ,[ 2 8 1 0 0 0 1
inflammatory lesions inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 2 , 1 9 1 0 0 0 1
[ 70% [ [ [ [ [ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 2 [- 2 8 1 0 0 0 1
flammatory lesions flammatory f fl fla flam BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 2 . 1 6 1 0 0 0 1
Fig. 3 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 .(- 3 9 1 0 0 0 1
ulation; pooled). ulation; u ul ula ulat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 ;)., 4 9 1 0 0 0 1
mean absolute mean m me mea mean BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 - 1 8 1 0 0 0 1
flammatory lesions flammatory f fl fla flam BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 4 no 0 10 1 0 0 0 1
with CAB with w wi wit with BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 4 .***.. 6 9 1 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 4 5 no 0 10 1 0 0 0 1
Treatment success treatment T Tr Tre Trea BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 - 1 10 1 0 0 0 1
from baseline from f fr fro from BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 ' 1 9 1 0 0 0 1
score of score s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 ()(). 5 10 1 0 0 0 1
with the with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 8 1 0 0 0 1
impute missing impute i im imp impu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 ../ 3 9 1 0 0 0 1
adapalene 0.15%/benzoyl adapalene a ad ada adap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 ./., 4 8 1 0 0 0 1
treat, LS treat, t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 , 1 4 1 0 0 0 1
Fig. 4 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 . 1 9 1 0 0 0 1
noninflammatory lesion noninflammatory n no non noni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 8 (; 2 9 1 0 0 0 1
pooled). Least-squares pooled). p po poo pool BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 8 ).- 3 10 1 0 0 0 1
in inflammatory in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 8 no 0 9 1 0 0 0 1
significantly greater significantly s si sig sign BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 8 . 1 8 1 0 0 0 1
***P \ ***p * ** *** ***P BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 ***.. 5 10 1 0 0 0 1
Markov Chain markov M Ma Mar Mark BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 no 0 8 1 0 0 0 1
missing values. missing m mi mis miss BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 ../- 4 9 1 0 0 0 1
palene 0.15%/benzoyl palene p pa pal pale BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 9 ./., 4 10 1 0 0 0 1
treat, LS treat, t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 , 1 4 1 0 0 0 1
1218 1218 1218 1 12 121 1218 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 5 11 no 0 1 1 1 0 0 0
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 11 ()():- 6 10 1 1 1 0 0
Fig. 5 fig. F Fi Fig Fig. BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 .. 2 8 1 0 0 0 1
photos showing photos p ph pho phot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ; 1 7 1 0 0 0 1
individual results individual i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 8 1 0 0 0 1
2023. Courtesy 2023. 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 0 .- 2 9 1 0 0 0 1
tors. Part tors. t to tor tors BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 . 1 10 1 0 0 0 1
Gold LS gold G Go Gol Gold BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 5 .,[].' 6 9 1 0 0 0 1
Severity Score, severity S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 ,./- 4 9 1 0 0 0 1
palene 0.15%/benzoyl palene p pa pal pale BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 ./., 4 10 1 0 0 0 1
lesions, NIL lesions, l le les lesi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 , 1 6 1 0 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 ()():- 6 10 1 1 1 0 0
1219 1219 1219 1 12 121 1219 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 5 10 no 0 1 1 1 0 0 0
To our to T To To To BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 ,- 2 7 1 0 0 0 1
ments in ments m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 no 0 8 1 0 0 0 1
any other any a an any any BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 9 1 0 0 0 1
or systemic or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 9 1 0 0 0 1
populations and populations p po pop popu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 9 1 0 0 0 1
ies. Specifically, ies. i ie ies ies. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ., 2 9 1 0 0 0 1
acne lesions acne a ac acn acne BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ([) 3 9 1 0 0 0 1
compared with compared c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 1 0 0 0 1
(range 25-66.2%) (range ( (r (ra (ran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 (-.)[-], 8 7 1 0 0 0 1
(21.9-68.7%) [30-37], (21.9-68.7%) ( (2 (21 (21. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 (.-.)[-], 9 8 1 0 0 0 1
(43.1-52.2%) [38]. (43.1-52.2%) ( (4 (43 (43. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 (.-.)[]., 9 8 1 0 0 0 1
with other with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 8 1 0 0 0 1
acne treatments acne a ac acn acne BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 1 0 0 0 1
treatment success treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,- 2 8 1 0 0 0 1
ated with ated a at ate ated BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 - 1 8 1 0 0 0 1
centage of centage c ce cen cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 (.-.) 5 8 1 0 0 0 1
[39]. [39]. [39]. [ [3 [39 [39] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 []. 3 1 1 0 0 0 1
The results the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 1 0 0 0 1
consistent with consistent c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 [](.), 6 10 1 0 0 0 1
with a with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -- 2 9 1 0 0 0 1
phase 3 phase p ph pha phas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 [], 3 9 1 0 0 0 1
superior to superior s su sup supe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 8 1 0 0 0 1
treatment success treatment t tr tre trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 10 1 0 0 0 1
(range 49.6-52.5%) (range ( (r (ra (ran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 (.-.)[ 6 9 1 0 0 0 1
in inflammatory in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 4 no 0 8 1 0 0 0 1
(range 71.0-80.1%). (range ( (r (ra (ran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 (.-.)., 7 8 1 0 0 0 1
treatment efficacy treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 10 1 0 0 0 1
component dyads component c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 [](.). 6 9 1 0 0 0 1
these findings, these t th the thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 ,-- 3 9 1 0 0 0 1
ments found ments m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 - 1 9 1 0 0 0 1
like CAB like l li lik like BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 ( 1 9 1 0 0 0 1
topical), retinoid topical), t to top topi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 ),(), 5 8 1 0 0 0 1
among the among a am amo amon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 8 1 0 0 0 1
treatments assessed treatments t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 9 1 0 0 0 1
and total and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 , 1 9 1 0 0 0 1
to oral to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 []. 3 5 1 0 0 0 1
Acne onset acne A Ac Acn Acne BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 8 1 0 0 0 1
during puberty, during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 , 1 8 1 0 0 0 1
puberty associated puberty p pu pub pube BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 - 1 9 1 0 0 0 1
lence among lence l le len lenc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 [,].- 5 9 1 0 0 0 1
lescents, acne lescents, l le les lesc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 , 1 9 1 0 0 0 1
as more as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 8 1 0 0 0 1
[42]. Further, [42]. [ [4 [42 [42] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 [].,[ 5 9 1 0 0 0 1
may be may m ma may may BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 1 0 0 5 4 ,, 2 8 1 0 0 0 1
Fig. 6 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 .- 2 8 1 0 0 0 1
week 12 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 8 (;).- 5 8 1 0 0 0 1
QoL domain qol Q Qo QoL QoL BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 8 ,-(- 4 8 1 0 0 0 1
provements) from provements) p pr pro prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 8 ) 1 9 1 0 0 0 1
greater with greater g gr gre grea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 8 .***. 5 8 1 0 0 0 1
vehicle. No vehicle. v ve veh vehi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 8 .. 2 9 1 0 0 0 1
lines indicate lines l li lin line BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 10 1 0 0 0 1
changes from changes c ch cha chan BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 10 .- 2 10 1 0 0 0 1
for self-perception, for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 10 -,-, 4 9 1 0 0 0 1
and 4-28 and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 10 --.-- 5 10 1 0 0 0 1
of Life of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 10 ,./ 3 9 1 0 0 0 1
adapalene 0.15%/benzoyl adapalene a ad ada adap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 ./., 4 9 1 0 0 0 1
treat, LS treat, t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 10 , 1 4 1 0 0 0 1
1220 1220 1220 1 12 122 1220 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 5 11 no 0 1 0 1 0 0 0
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 11 ()():- 6 10 0 1 1 0 0
Table 2 table T Ta Tab Tabl BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 10 1 1 0 0 1
week 12 week w we wee week BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 () 2 5 1 1 0 0 1
Participants, n participants, P Pa Par Part BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 10 1 1 0 0 1
CAB gel cab C CA CAB CAB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 5 1 1 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 () 2 6 1 1 0 0 1
Vehicle gel vehicle V Ve Veh Vehi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 10 1 1 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 () 2 8 1 1 0 0 1
Reporting any reporting R Re Rep Repo BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 0 no 0 10 1 1 0 0 1
66 (27.3) 66 6 66 66 66 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 0 (.) 3 5 1 1 0 0 1
10 (8.3) 10 1 10 10 10 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 0 (.) 3 4 1 1 0 0 1
Reporting any reporting R Re Rep Repo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 1 no 0 10 1 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 1 no 0 1 1 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 1 no 0 1 1 0 0 0 1
Discontinued study discontinued D Di Dis Disc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 10 0 0 0 0 1
because of because b be bec beca BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 7 0 0 0 0 1
7 (2.9) 7 7 7 7 7 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 1 (.) 3 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 1 no 0 2 0 0 0 0 1
Severity of severity S Se Sev Seve BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 10 0 0 0 0 1
Mild Mild mild M Mi Mil Mild BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 5 0 0 0 0 1
40 (16.5) 40 4 40 40 40 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 1 (.) 3 10 0 0 0 0 1
8 (6.6) 8 8 8 8 8 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 1 (.) 3 8 0 0 0 0 1
Moderate Moderate moderate M Mo Mod Mode BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 2 no 0 10 0 0 0 0 1
23 (9.5) 23 2 23 23 23 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 2 (.) 3 10 0 0 0 0 1
2 (1.7) 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 2 (.) 3 8 0 0 0 0 1
Severe b severe S Se Sev Seve BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 2 no 0 10 0 0 0 0 1
3 (1.2) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 2 (.) 3 8 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 2 no 0 2 0 0 0 0 1
Relationship to relationship R Re Rel Rela BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 2 no 0 10 0 0 0 0 1
Related Related related R Re Rel Rela BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 2 no 0 8 0 0 0 0 1
48 (19.8) 48 4 48 48 48 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 2 (.) 3 10 0 0 0 0 1
2 (1.7) 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 2 (.) 3 8 0 0 0 0 1
Unrelated Unrelated unrelated U Un Unr Unre BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 10 0 0 0 0 1
18 (7.4) 18 1 18 18 18 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 3 (.) 3 9 0 0 0 0 1
8 (6.6) 8 8 8 8 8 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 3 (.) 3 8 0 0 0 0 1
Related TEAEs related R Re Rel Rela BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 10 0 0 0 0 1
treatment group treatment t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 3 0 0 0 0 1
Application site application A Ap App Appl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 10 0 0 0 0 1
31 (12.8) 31 3 31 31 31 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 3 (.) 3 4 0 0 0 0 1
1 1 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 3 no 0 0 0 0 0 0 1
Application site application A Ap App Appl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 4 no 0 10 0 0 0 0 1
7 (2.9) 7 7 7 7 7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 4 (.) 3 3 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 4 no 0 0 0 0 0 0 1
Erythema Erythema erythema E Er Ery Eryt BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 4 no 0 10 1 0 0 0 1
6 (2.5) 6 6 6 6 6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 4 (.) 3 8 1 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 4 no 0 2 1 0 0 0 1
Application site application A Ap App Appl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 4 (.) 3 10 1 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 4 no 0 0 1 0 0 0 1
CAB clindamycin cab C CA CAB CAB BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 4 ././- 5 9 1 0 0 0 1
zoyl peroxide zoyl z zo zoy zoyl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 4 .,, 3 10 1 0 0 0 1
treatment-emergent adverse treatment-emergent t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 4 - 1 6 1 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 6 5 no 0 10 1 0 0 0 1
Prematurely discontinued prematurely P Pr Pre Prem BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 9 1 0 0 0 1
an adverse an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 5 ():( 4 9 1 0 0 0 1
study drug); study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 );();- 6 9 1 0 0 0 1
erate swelling erate e er era erat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ,,- 3 9 1 0 0 0 1
erate erythema, erate e er era erat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 , 1 8 1 0 0 0 1
(related); moderate (related); ( (r (re (rel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ();();- 7 9 1 0 0 0 1
erate application erate e er era erat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ();- 4 9 1 0 0 0 1
cation site cation c ca cat cati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 (); 3 10 1 0 0 0 1
(unrelated) (unrelated) (unrelated) ( (u (un (unr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 () 2 1 1 0 0 0 1
b b b b b b b BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 6 7 no 0 10 1 0 0 0 1
All were all A Al All All BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 (): 3 9 1 0 0 0 1
site burn site s si sit site BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 (); 3 10 1 0 0 0 1
and application and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 ; 1 8 1 0 0 0 1
c All c c c c c BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 6 7 no 0 9 1 0 0 0 1
Fig. 7 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 .(- 3 9 1 0 0 0 1
tion; pooled). tion; t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 8 ;)., 4 9 1 0 0 0 1
erythema, itching, erythema, e er ery eryt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 8 ,,, 3 8 1 0 0 0 1
treatment were treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 , 1 8 1 0 0 0 1
decreases at decreases d de dec decr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 10 1 0 0 0 1
values by values v va val valu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 . 1 8 1 0 0 0 1
(N values (n ( (N (N (N BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 (). 3 9 1 0 0 0 1
hyperpigmentation and hyperpigmentation h hy hyp hype BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 8 no 0 8 1 0 0 0 1
no trends no n no no no BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 ., 2 9 1 0 0 0 1
CAB clindamycin cab C CA CAB CAB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 ././- 5 8 1 0 0 0 1
zoyl peroxide zoyl z zo zoy zoyl BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 8 ., 2 6 1 0 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 ()():- 6 10 1 1 1 0 0
1221 1221 1221 1 12 122 1221 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 6 11 no 0 1 1 1 0 0 0
presentation, and presentation, p pr pre pres BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 0 0 0 0 1
distinct those distinct d di dis dist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 - 1 8 0 0 0 0 1
with those with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ('''')[]. 9 10 0 0 0 0 1
Pooling data pooling P Po Poo Pool BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 - 1 9 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 0 - 1 9 0 0 0 0 1
ysis of ysis y ys ysi ysis BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 , 1 10 0 0 0 0 1
similar to similar s si sim simi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 .- 2 9 0 0 0 0 1
ple imputation ple p pl ple ple BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,- 2 9 0 0 0 0 1
ment at ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 . 1 9 0 0 0 0 1
72.9% reductions 72.9% 7 72 72. 72.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .- 2 8 0 0 0 0 1
flammatory lesions flammatory f fl fla flam BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 , 1 9 0 0 0 0 1
respectively (overall respectively r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 (. 2 8 0 0 0 0 1
73.0%), and 73.0%), 7 73 73. 73.0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 .),. 4 8 0 0 0 0 1
participants (overall participants p pa par part BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 (.). 4 9 0 0 0 0 1
CAB is cab C CA CAB CAB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 3 - 1 9 0 0 0 0 1
related acne related r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 ., 2 9 0 0 0 0 1
three ingredients three t th thr thre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 ,-- 3 9 0 0 0 0 1
ment regimen ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 3 - 1 9 0 0 0 0 1
additionally benefit additionally a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 , 1 8 0 0 0 0 1
which has which w wh whi whic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 8 0 0 0 0 1
improved when improved i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 9 0 0 0 0 1
product versus product p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 8 0 0 0 0 1
[44]. This [44]. [ [4 [44 [44] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 3 []. 3 9 0 0 0 0 1
aged \ aged a ag age aged BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 , 1 8 0 0 0 0 1
particularly low particularly p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 [].,- 5 9 0 0 0 0 1
cated for cated c ca cat cate BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 3 no 0 10 0 0 0 0 1
Fig. 8 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 . 1 8 1 0 0 0 1
week 12 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 6 no 0 9 1 0 0 0 1
(ITT populations). (itt ( (I (IT (ITT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 6 ().[] 5 9 1 0 0 0 1
pooled analysis pooled p po poo pool BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 6 , 1 9 1 0 0 0 1
superior to superior s su sup supe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 6 , 1 10 1 0 0 0 1
of participants, of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 6 ,[ 2 9 1 0 0 0 1
and noninflammatory and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 6 .***.;## 8 9 1 0 0 0 1
P \ p P P P P BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 6 .,###.. 7 8 1 0 0 0 1
adjusted for adjusted a ad adj adju BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 . 1 9 1 0 0 0 1
participants achieving participants p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 - 1 9 1 0 0 0 1
in Evaluator's in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 9 '() 3 10 1 0 0 0 1
or 1 or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 ().., 5 8 1 0 0 0 1
peroxide 3.1%, peroxide p pe per pero BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 .,., 4 8 1 0 0 0 1
clindamycin phosphate clindamycin c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 ././ 4 8 1 0 0 0 1
peroxide 3.1% peroxide p pe per pero BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 .,,, 4 9 1 0 0 0 1
VEH vehicle veh V VE VEH VEH BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 9 no 0 2 1 0 0 0 1
1222 1222 1222 1 12 122 1222 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 6 11 no 0 1 1 1 0 0 0
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 ()():- 6 10 1 1 1 0 0
as a as a as as as BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
\ 12 \ \ \ \ \ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 0 . 1 7 0 0 0 0 1
Combination treatment combination C Co Com Comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
ingredients carries ingredients i in ing ingr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 - 1 9 0 0 0 0 1
bility concerns. bility b bi bil bili BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 .,, 3 9 0 0 0 0 1
gel was gel g ge gel gel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 8 0 0 0 0 1
consistent with consistent c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
from the from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 [,]. 4 8 0 0 0 0 1
Further, in further, F Fu Fur Furt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 ,, 2 9 0 0 0 0 1
and tolerability and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
better than better b be bet bett BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 /- 2 8 0 0 0 0 1
lar to lar l la lar lar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 /,- 3 8 0 0 0 0 1
cating that cating c ca cat cati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
combination did combination c co com comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 []. 3 9 0 0 0 0 1
the phase the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 8 0 0 0 0 1
with CAB with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 .(). 4 8 0 0 0 0 1
Most TEAEs most M Mo Mos Most BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 --, 3 8 0 0 0 0 1
and the and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
low in low l lo low low BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 0 (). 3 8 0 0 0 0 1
may contribute may m ma may may BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 1 0 0 6 0 '- 2 8 0 0 0 0 1
bility profile. bility b bi bil bili BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 .- 2 8 0 0 0 0 1
meric formulation meric m me mer meri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 7 0 0 0 0 1
allow for allow a al all allo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 9 0 0 0 0 1
improves penetration improves i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
unit, which unit, u un uni unit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 7 0 0 0 0 1
enhancing tolerability enhancing e en enh enha BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
[10, 46]. [10, [ [1 [10 [10, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 [,]. 4 8 0 0 0 0 1
vehicle may vehicle v ve veh vehi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 7 0 0 0 0 1
with many with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 7 0 0 0 0 1
and/or retinoids. and/or a an and and/ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 /.-- 4 8 0 0 0 0 1
erties of erties e er ert erti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 - 1 8 0 0 0 0 1
erating effect erating e er era erat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
and adapalene and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 [].,- 5 8 0 0 0 0 1
ents are ents e en ent ents BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 -, 2 9 0 0 0 0 1
that contains that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
and is and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,, 2 9 0 0 0 0 1
agents, and agents, a ag age agen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,. 2 4 0 0 0 0 1
Acne can acne A Ac Acn Acne BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 -, 2 7 0 0 0 0 1
social relationships, social s so soc soci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,-- 3 9 0 0 0 0 1
ing, resulting ing, i in ing ing, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,' 2 9 0 0 0 0 1
quality of quality q qu qua qual BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 []., 4 10 0 0 0 0 1
treatments that treatments t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 9 0 0 0 0 1
but also but b bu but but BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 9 0 0 0 0 1
analysis, CAB-treated analysis, a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 ,-- 3 8 0 0 0 0 1
cantly greater cantly c ca can cant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 7 0 0 0 0 1
week 12 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 -- 2 7 0 0 0 0 1
pared with pared p pa par pare BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 -,- 3 8 0 0 0 0 1
cating greater cating c ca cat cati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 . 1 8 0 0 0 0 1
Some limitations some S So Som Some BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 0 0 0 0 1
interpretation of interpretation i in int inte BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 .- 2 7 0 0 0 0 1
treatment time treatment t tr tre trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 no 0 9 0 0 0 0 1
compared with compared c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 , 1 8 0 0 0 0 1
which may which w wh whi whic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 no 0 7 0 0 0 0 1
benefits to benefits b be ben bene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 6 []., 4 9 0 0 0 0 1
sustained effects sustained s su sus sust BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 -- 2 9 0 0 0 0 1
acne within acne a ac acn acne BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 -[]- 4 8 0 0 0 0 1
gests further gests g ge ges gest BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 6 no 0 8 0 0 0 0 1
continued treatment, continued c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 , 1 7 0 0 0 0 1
inflammatory and inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 6 no 0 7 0 0 0 0 1
counts continued counts c co cou coun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 6 no 0 8 0 0 0 0 1
preceding the preceding p pr pre prec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 - 1 8 0 0 0 0 1
dence of dence d de den denc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 6 .- 2 9 0 0 0 0 1
ysis also ysis y ys ysi ysis BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 6 no 0 9 0 0 0 0 1
presentation and presentation p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 no 0 9 0 0 0 0 1
across demographic across a ac acr acro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 , 1 9 0 0 0 0 1
age, and age, a ag age age, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 ,; 2 9 0 0 0 0 1
post hoc post p po pos post BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 6 . 1 9 0 0 0 0 1
Additionally, interobserver additionally, A Ad Add Addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 6 , 1 9 0 0 0 0 1
can be can c ca can can BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 no 0 8 0 0 0 0 1
assessments such assessments a as ass asse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 []., 4 9 0 0 0 0 1
phase 3 phase p ph pha phas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 no 0 9 0 0 0 0 1
CAB in cab C CA CAB CAB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 7 6 -- 2 8 0 0 0 0 1
facial acne; facial f fa fac faci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 ; 1 10 0 0 0 0 1
of these of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 no 0 9 0 0 0 0 1
of acne of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 -. 2 9 0 0 0 0 1
the study the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 , 1 9 0 0 0 0 1
trunk are trunk t tr tru trun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 no 0 9 0 0 0 0 1
to apply to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 (, 2 9 0 0 0 0 1
chest, upper chest, c ch che ches BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 6 ,,). 4 6 0 0 0 0 1
CONCLUSION CONCLUSION conclusion C CO CON CONC BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 10 0 0 0 0 1
In two in I In In In BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 9 ,-,- 4 9 0 0 0 0 1
cle-controlled clinical cle-controlled c cl cle cle- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 9 - 1 9 0 0 0 0 1
with moderate-to-severe with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 --, 3 9 0 0 0 0 1
(clindamycin (clindamycin (clindamycin ( (c (cl (cli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 9 ( 1 2 0 0 0 0 1
phosphate phosphate phosphate p ph pho phos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 2 0 0 0 0 1
1.2%/adapalene 1.2%/adapalene 1.2%/adapalene 1 1. 1.2 1.2% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 ./ 2 3 0 0 0 0 1
0.15%/BPO 3.1%) 0.15%/bpo 0 0. 0.1 0.15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 ./.)- 5 8 0 0 0 0 1
cacy to cacy c ca cac cacy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 9 - 1 9 0 0 0 0 1
treatment. CAB treatment. t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 .[ 2 8 0 0 0 0 1
reductions from reductions r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 9 0 0 0 0 1
noninflammatory lesions, noninflammatory n no non noni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 9 , 1 9 0 0 0 0 1
50% of 50% 5 50 50% 50% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 , 1 9 0 0 0 0 1
tolerability profile. tolerability t to tol tole BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 9 . 1 10 0 0 0 0 1
CAB gel-the cab C CA CAB CAB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 --,-- 5 9 0 0 0 0 1
tion topical tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 9 - 1 8 0 0 0 0 1
effective treatment effective e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 ,- 2 9 0 0 0 0 1
cents, and cents, c ce cen cent BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 9 ,--. 4 9 0 0 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 11 ()():- 6 10 0 1 1 0 0
1223 1223 1223 1 12 122 1223 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 7 11 no 0 1 0 1 0 0 0
ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS acknowledgements A AC ACK ACKN BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 10 0 1 0 0 1
We thank we W We We We BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 10 0 1 0 0 1
Medical Writing/Editorial medical M Me Med Medi BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 /- 2 6 0 0 0 0 1
ical writing ical i ic ica ical BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
Lewis, PhD lewis, L Le Lew Lewi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ,,- 3 9 0 0 0 0 1
scott Medical scott s sc sco scot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 7 0 , 1 9 0 0 0 0 1
Health Group, health H He Hea Heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 0 ,.(,), 6 10 0 0 0 0 1
financial support financial f fi fin fina BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 9 0 0 0 0 1
Ortho Dermatologics ortho O Or Ort Orth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
Health US, health H He Hea Heal BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 0 ,. 2 3 0 0 0 0 1
Author Contributions. author A Au Aut Auth BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 1 .., 3 7 0 0 0 0 1
Linda Stein linda L Li Lin Lind BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 7 1 ,,. 3 9 0 0 0 0 1
Weiss, Julie weiss, W We Wei Weis BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 1 ,.,., 5 9 0 0 0 0 1
Christopher G. christopher C Ch Chr Chri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 7 1 .,,. 4 9 0 0 0 0 1
Tanghetti, Lawrence tanghetti, T Ta Tan Tang BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 1 ,., 3 8 0 0 0 0 1
Baldwin, Zoe baldwin, B Ba Bal Bald BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 1 ,.,., 5 9 0 0 0 0 1
George Han, george G Ge Geo Geor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 7 1 ,., 3 8 0 0 0 0 1
Sadick, Mary sadick, S Sa Sad Sadi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 1 ,.,(), 6 9 0 0 0 0 1
Wiliam Philip wiliam W Wi Wil Wili BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 1 - 1 9 0 0 0 0 1
tributions to tributions t tr tri trib BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
work; drafted work; w wo wor work BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ;/; 3 9 0 0 0 0 1
approved the approved a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ; 1 10 0 0 0 0 1
to be to t to to to BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 . 1 10 0 0 0 0 1
Funding. The funding. F Fu Fun Fund BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 2 . 1 8 0 0 0 0 1
Fee were fee F Fe Fee Fee BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 2 . 1 10 0 0 0 0 1
Dermatologics is dermatologics D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 2 no 0 9 0 0 0 0 1
US, LLC. us, U US US, US, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 8 2 ,. 2 1 0 0 0 0 1
Data Availability. data D Da Dat Data BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 3 . 1 9 0 0 0 0 1
during and/or during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 3 / 1 9 0 0 0 0 1
study are study s st stu stud BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 3 . 1 10 0 0 0 0 1
Declarations Declarations declarations D De Dec Decl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 3 no 0 10 0 0 0 0 1
Conflict of conflict C Co Con Conf BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 3 .. 2 8 0 0 0 0 1
served as served s se ser serv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 3 ,, 2 10 0 0 0 0 1
an investigator an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 3 ,, 2 8 0 0 0 0 1
Health, Galderma, health, H He Hea Heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 3 ,,,- 4 8 0 0 0 0 1
logics, and logics, l lo log logi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 3 ,. 2 8 0 0 0 0 1
served as served s se ser serv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 3 / 1 9 0 0 0 0 1
Ortho Dermatologics, ortho O Or Ort Orth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 3 ,,, 3 8 0 0 0 0 1
Incyte, Novartis, incyte, I In Inc Incy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 3 ,,,,, 5 9 0 0 0 0 1
UCB, Arcutis, ucb, U UC UCB UCB, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 3 ,,. 3 9 0 0 0 0 1
as an as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 3 ,,,- 4 9 0 0 0 0 1
sultant for sultant s su sul sult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 3 .. 2 8 0 0 0 0 1
Weiss is weiss W We Wei Weis BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 3 ,,,/ 4 9 0 0 0 0 1
researcher for researcher r re res rese BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,, 2 8 0 0 0 0 1
Janssen Biotech, janssen J Ja Jan Jans BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 5 ,,, 3 9 0 0 0 0 1
Biotech, DermTech, biotech, B Bi Bio Biot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,..- 5 9 0 0 0 0 1
per has per p pe per per BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,- 2 9 0 0 0 0 1
rall, BioPharmX, rall, r ra ral rall BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,,, 5 9 0 0 0 0 1
Foamix, Galderma, foamix, F Fo Foa Foam BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,-,- 5 8 0 0 0 0 1
matologics, and matologics, m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ,.. 3 8 0 0 0 0 1
Rosso has rosso R Ro Ros Ross BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,, 2 9 0 0 0 0 1
and/or speaker and/or a an and and/ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 /,- 3 8 0 0 0 0 1
Vie, Amgen, vie, V Vi Vie Vie, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 ,,,,, 5 8 0 0 0 0 1
Heath, Galderma, heath, H He Hea Heat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 ,,,,- 5 9 0 0 0 0 1
Posay, LEO posay, P Po Pos Posa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,',- 6 9 0 0 0 0 1
peutics, Pfizer, peutics, p pe peu peut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,,. 5 9 0 0 0 0 1
Christopher G. christopher C Ch Chr Chri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 5 .- 2 9 0 0 0 0 1
tigator for tigator t ti tig tiga BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,- 4 9 0 0 0 0 1
vella; a vella; v ve vel vell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ;,,, 4 10 0 0 0 0 1
Arcutis, Eli arcutis, A Ar Arc Arcu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,/, 4 8 0 0 0 0 1
Pharma, Novartis, pharma, P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,, 4 9 0 0 0 0 1
Sanofi-Regeneron, and sanofi-regeneron, S Sa San Sano BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 -,; 3 9 0 0 0 0 1
and received and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,, 2 9 0 0 0 0 1
LEO Pharma, leo L LE LEO LEO BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 8 5 ,. 2 8 0 0 0 0 1
as advisor, as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,, 2 9 0 0 0 0 1
AbbVie, Almirall, abbvie, A Ab Abb AbbV BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,,,, 6 10 0 0 0 0 1
EPI Health, epi E EP EPI EPI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,,, 5 9 0 0 0 0 1
J&J, LaRoche-Posay, j&j, J J& J&J J&J, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,-,,- 5 8 0 0 0 0 1
matologics, Regeneron, matologics, m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,, 4 8 0 0 0 0 1
Verrica, and verrica, V Ve Ver Verr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,.. 3 9 0 0 0 0 1
as speaker as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,, 2 9 0 0 0 0 1
Sun Pharma, sun S Su Sun Sun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 8 5 ,,,, 4 8 0 0 0 0 1
Dermira; served dermira; D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ;/ 2 9 0 0 0 0 1
for Hologic, for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,,- 3 8 0 0 0 0 1
derma; and derma; d de der derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ;.- 3 9 0 0 0 0 1
ence F. ence e en enc ence BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 . 1 9 0 0 0 0 1
consulting services consulting c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,,, 3 9 0 0 0 0 1
Dermira, Dermavant, dermira, D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,, 4 9 0 0 0 0 1
Galderma, Incyte, galderma, G Ga Gal Gald BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,,,, 6 9 0 0 0 0 1
Regeneron Pharmaceuticals, regeneron R Re Reg Rege BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,.,- 4 8 0 0 0 0 1
zyme, and zyme, z zy zym zyme BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ,; 2 8 0 0 0 0 1
support (to support s su sup supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 5 (), 3 9 0 0 0 0 1
Health, Dermira, health, H He Hea Heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 ,,,- 4 8 0 0 0 0 1
derma, Incyte, derma, d de der derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,- 4 9 0 0 0 0 1
cals, Inc. cals, c ca cal cals BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ,.. 3 9 0 0 0 0 1
has served has h ha has has BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,, 2 8 0 0 0 0 1
speakers' bureaus speakers' s sp spe spea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ',,- 4 9 0 0 0 0 1
mix, Galderma, mix, m mi mix mix, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,,,, 4 9 0 0 0 0 1
and Sun and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 .. 2 8 0 0 0 0 1
funding from funding f fu fun fund BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 .. 2 9 0 0 0 0 1
Callender has callender C Ca Cal Call BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 5 ,- 2 9 0 0 0 0 1
sultant, or sultant, s su sul sult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,, 3 9 0 0 0 0 1
Aerolase, AbbVie, aerolase, A Ae Aer Aero BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,,,, 4 9 0 0 0 0 1
1224 1224 1224 1 12 122 1224 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 8 11 no 0 1 0 1 0 0 0
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 11 ()():- 6 10 0 1 1 0 0
Avita Medical, avita A Av Avi Avit BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,, 4 9 0 0 0 0 1
Eli Lilly, eli E El Eli Eli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 0 ,,, 3 7 0 0 0 0 1
Aesthetics, L'Ore aesthetics, A Ae Aes Aest BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 ,',,- 5 9 0 0 0 0 1
zer, Prollineum, zer, z ze zer zer, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,,, 5 9 0 0 0 0 1
SkinBetter science, skinbetter S Sk Ski Skin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,, 3 9 0 0 0 0 1
UCB, and ucb, U UC UCB UCB, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,. 2 9 0 0 0 0 1
an investigator, an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 0 ,/, 3 9 0 0 0 0 1
for AbbVie, for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ,,, 3 8 0 0 0 0 1
Bond Avillion, bond B Bo Bon Bond BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 8 0 ,-,, 4 9 0 0 0 0 1
Eli Lilly, eli E El Eli Eli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 0 ,,,,, 5 9 0 0 0 0 1
Ortho Dermatologics, ortho O Or Ort Orth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,, 3 8 0 0 0 0 1
Regeneron, Sanofi regeneron, R Re Reg Rege BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,, 3 8 0 0 0 0 1
UCB. Melinda ucb. U UC UCB UCB. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 .. 2 8 0 0 0 0 1
investigator/consultant or investigator/consultant i in inv inve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 /, 2 9 0 0 0 0 1
Akros Pharma, akros A Ak Akr Akro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,, 3 9 0 0 0 0 1
Aslan, Aristea, aslan, A As Asl Asla BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,,,- 6 9 0 0 0 0 1
ringer Ingelheim, ringer r ri rin ring BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,- 3 8 0 0 0 0 1
mira, Dermavant, mira, m mi mir mira BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,,, 5 8 0 0 0 0 1
Incyte, Inmagene, incyte, I In Inc Incy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,, 4 8 0 0 0 0 1
Pharma, MedImmune, pharma, P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,,, 5 8 0 0 0 0 1
Nimbus, Novartis, nimbus, N Ni Nim Nimb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,- 4 8 0 0 0 0 1
ceuticals, Inc., ceuticals, c ce ceu ceut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,.,,,, 6 9 0 0 0 0 1
Pharma, Takeda, pharma, P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,,- 5 8 0 0 0 0 1
tyx. Neil tyx. t ty tyx tyx. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ., 2 9 0 0 0 0 1
as a as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ,,,/ 4 9 0 0 0 0 1
other and other o ot oth othe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 // 2 9 0 0 0 0 1
research funding research r re res rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 0 ,,- 3 9 0 0 0 0 1
gan, Anacor gan, g ga gan gan, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,- 3 8 0 0 0 0 1
maceuticals, Bausch maceuticals, m ma mac mace BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,,, 5 10 0 0 0 0 1
Carma Laboratories, carma C Ca Car Carm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 0 ,,- 3 8 0 0 0 0 1
poration, Cutera, poration, p po por pora BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,- 4 8 0 0 0 0 1
ticals, Eclipse ticals, t ti tic tica BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,, 3 9 0 0 0 0 1
Endo International, endo E En End Endo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,, 2 9 0 0 0 0 1
Laboratories, Galderma, laboratories, L La Lab Labo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 ,, 2 7 0 0 0 0 1
Group, Hydropeptide, group, G Gr Gro Grou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 ,,,- 4 8 0 0 0 0 1
trata, Novartis, trata, t tr tra trat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,, 3 10 0 0 0 0 1
Medical Technologies, medical M Me Med Medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 ,', 3 8 0 0 0 0 1
Regeneron, Roche regeneron, R Re Reg Rege BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,, 3 8 0 0 0 0 1
Solta Medical, solta S So Sol Solt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,- 3 9 0 0 0 0 1
cal, Vanda cal, c ca cal cal, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,- 3 8 0 0 0 0 1
cept. Mary cept. c ce cep cept BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 .., 3 8 0 0 0 0 1
investigator, and/or investigator, i in inv inve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ,/ 2 8 0 0 0 0 1
Ortho Dermatologics, ortho O Or Ort Orth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,- 3 8 0 0 0 0 1
lus, Revance, lus, l lu lus lus, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,,- 5 8 0 0 0 0 1
tryx, Therapeutics tryx, t tr try tryx BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,, 4 10 0 0 0 0 1
Cutera, In cutera, C Cu Cut Cute BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,. 4 7 0 0 0 0 1
Edward (Ted) edward E Ed Edw Edwa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 0 (), 3 9 0 0 0 0 1
consultant and/or consultant c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 /- 2 8 0 0 0 0 1
logics, AbbVie, logics, l lo log logi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ,,,,,- 6 9 0 0 0 0 1
mavant, EPI mavant, m ma mav mava BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,,, 4 8 0 0 0 0 1
Pharma, Novartis, pharma, P Ph Pha Phar BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ,,,,, 5 10 0 0 0 0 1
UCB, Endo ucb, U UC UCB UCB, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ,,,- 4 8 0 0 0 0 1
rasi, Sirnaomics, rasi, r ra ras rasi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 6 ,,, 3 9 0 0 0 0 1
Pharmaceuticals, Cara pharmaceuticals, P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 ,, 2 8 0 0 0 0 1
Biosciences, Mindera, biosciences, B Bi Bio Bios BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ,,,, 4 9 0 0 0 0 1
AiViva Biopharma, aiviva A Ai AiV AiVi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ,,, 3 9 0 0 0 0 1
Dr Reddy's, dr D Dr Dr Dr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ',. 3 9 0 0 0 0 1
Werschler has werschler W We Wer Wers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 no 0 8 0 0 0 0 1
Ortho Dermatologics. ortho O Or Ort Orth BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 . 1 4 0 0 0 0 1
Ethical Approval. ethical E Et Eth Ethi BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 .- 2 8 0 0 0 0 1
ried out ried r ri rie ried BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 no 0 9 0 0 0 0 1
Clinical Practice clinical C Cl Cli Clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 () 2 9 0 0 0 0 1
Helsinki. Study helsinki. H He Hel Hels BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 .- 2 9 0 0 0 0 1
ters were ters t te ter ters BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 - 1 9 0 0 0 0 1
tional review tional t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 (,, 3 9 0 0 0 0 1
MD, USA). md, M MD MD, MD, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 ,).- 4 9 0 0 0 0 1
dians provided dians d di dia dian BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 no 0 9 0 0 0 0 1
entering the entering e en ent ente BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 no 0 10 0 0 0 0 1
were derived. were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 . 1 9 0 0 0 0 1
obtained from obtained o ob obt obta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 no 0 9 0 0 0 0 1
whom identifying whom w wh who whom BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 / 1 9 0 0 0 0 1
included in included i in inc incl BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 . 1 5 0 0 0 0 1
Open Access. open O Op Ope Open BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 8 . 1 8 0 0 0 0 1
a Creative a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 9 8 -- 2 7 0 0 0 0 1
mercial 4.0 mercial m me mer merc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 8 .,- 3 8 0 0 0 0 1
mits any mits m mi mit mits BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 8 -,, 3 7 0 0 0 0 1
adaptation, distribution adaptation, a ad ada adap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 8 , 1 8 0 0 0 0 1
any medium any a an any any BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 8 , 1 8 0 0 0 0 1
appropriate credit appropriate a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 8 () 2 9 0 0 0 0 1
the source, the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 8 , 1 8 0 0 0 0 1
Commons licence, commons C Co Com Comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 9 8 , 1 9 0 0 0 0 1
made. The made. m ma mad made BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 8 . 1 9 0 0 0 0 1
in this in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 8 ' 1 9 0 0 0 0 1
Creative Commons creative C Cr Cre Crea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 8 , 1 8 0 0 0 0 1
otherwise in otherwise o ot oth othe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 8 . 1 9 0 0 0 0 1
material is material m ma mat mate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 8 ' 1 10 0 0 0 0 1
Commons licence commons C Co Com Comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 9 8 no 0 8 0 0 0 0 1
permitted by permitted p pe per perm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 8 no 0 9 0 0 0 0 1
permitted use, permitted p pe per perm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 8 ,- 2 9 0 0 0 0 1
sion directly sion s si sio sion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 8 . 1 9 0 0 0 0 1
a copy a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 9 8 ,:// 4 7 0 0 0 0 1
creativecommons.org/licenses/by-nc/4.0/. creativecommons.org/licenses/by-nc/4.0/. creativecommons.org/licenses/by-nc/4.0/. c cr cre crea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 8 .//-/./. 8 8 0 0 0 0 1
REFERENCES REFERENCES references R RE REF REFE BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 9 11 no 0 10 0 0 0 0 1
1. Bickers 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 11 .,,,. 5 10 0 1 0 0 1
of skin of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 11 :- 2 9 0 1 0 0 1
can Academy can c ca can can BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 11 no 0 8 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 11 ()():- 6 10 0 1 1 0 0
1225 1225 1225 1 12 122 1225 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 9 11 no 0 1 0 1 0 0 0
Society for society S So Soc Soci BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 10 0 1 0 0 1
Dermatol. 2006;55(3):490-500. dermatol. D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 .;():-. 7 6 0 1 0 0 1
2. AL, 2. 2 2. 2. 2. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,,,.- 6 8 0 1 0 0 1
lines of lines l li lin line BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 10 0 1 0 0 1
J Am j J J J J BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 9 0 .;():-.. 8 8 0 1 0 0 1
3. Gollnick 3. 3 3. 3. 3. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .,,,. 5 9 0 0 0 0 1
Pathogenesis and pathogenesis P Pa Pat Path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 0 0 0 1
acne. J acne. a ac acn acne BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ..;():-. 8 7 0 0 0 0 1
4. Kircik 4. 4 4. 4. 4. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 .. 2 10 0 0 0 0 1
topical ance topical t to top topi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 .. 2 8 0 0 0 0 1
2011;4(11):30-3. 2011;4(11):30-3. 2011;4(11):30-3. 2 20 201 2011 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 ;():-. 6 3 0 0 0 0 1
5. Moradi 5. 5 5. 5. 5. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 1 .,,,- 5 9 0 0 0 0 1
man SR. man m ma man man BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 1 . 1 9 0 0 0 0 1
treatment. Patient treatment. t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 ..;:-. 6 10 0 0 0 0 1
6. Nast 6. 6 6. 6. 6. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 1 .,,,.- 6 10 0 0 0 0 1
based (S3) based b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 ()- 3 8 0 0 0 0 1
update 2016 update u up upd upda BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 1 -. 2 8 0 0 0 0 1
Venereol. 2016;30(8):1261-8. venereol. V Ve Ven Vene BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 1 .;():-. 7 5 0 0 0 0 1
7. FDA 7. 7 7. 7. 7. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 2 .(, 3 9 0 0 0 0 1
adapalene and adapalene a ad ada adap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 2 ) 1 10 0 0 0 0 1
treatment of treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 no 0 10 0 0 0 0 1
of age of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 .. 2 9 0 0 0 0 1
20, 20, 20, 2 20 20, 20, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 2 , 1 0 0 0 0 0 1
2023. 2023. 2023. 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 2 . 1 1 0 0 0 0 1
https://ir.bauschhealth.com/news- https://ir.bauschhealth.com/news- https://ir.bauschhealth.com/news- h ht htt http BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 1 9 2 ://../- 7 6 0 0 0 0 1
releases/2023/10-20-2023. Accessed releases/2023/10-20-2023. r re rel rele BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 2 //--.. 6 9 0 0 0 0 1
8. Del 8. 8 8. 8. 8. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 2 .,.- 4 9 0 0 0 0 1
inflammatory properties inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 2 no 0 8 0 0 0 0 1
treatment of treatment t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 2 ..;():-. 8 10 0 0 0 0 1
9. Armillei 9. 9 9. 9. 9. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 3 .,,,.- 6 10 0 0 0 0 1
entific rationale entific e en ent enti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 3 no 0 10 0 0 0 0 1
use in use u us use use BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 3 . 1 8 0 0 0 0 1
Antibiotics. 2024;13(3):270. antibiotics. A An Ant Anti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 3 .;():. 6 5 0 0 0 0 1
10. Baldwin 10. 1 10 10. 10. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 3 .,,,. 5 10 0 0 0 0 1
of topical of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 3 :- 2 8 0 0 0 0 1
ment. Am ment. m me men ment BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 3 ..;():-. 8 8 0 0 0 0 1
11. Shroot 11. 1 11 11. 11. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 4 .,. 3 10 0 0 0 0 1
adapalene. J adapalene. a ad ada adap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 4 ..;(): 6 8 0 0 0 0 1
S96-103. S96-103. s96-103. S S9 S96 S96- BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 4 -. 2 1 0 0 0 0 1
12. Dutil 12. 1 12 12. 12. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 4 ..: 3 10 0 0 0 0 1
efficacy in efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 4 .. 2 9 0 0 0 0 1
2010;15(10):5-7. 2010;15(10):5-7. 2010;15(10):5-7. 2 20 201 2010 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 4 ;():-. 6 3 0 0 0 0 1
13. Waller 13. 1 13 13. 13. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 4 .,,,.'''' 9 10 0 0 0 0 1
properties of properties p pr pro prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 4 no 0 8 0 0 0 0 1
resemble salicylic resemble r re res rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 4 . 1 8 0 0 0 0 1
Physiol. 2006;19(5):283-9. physiol. P Ph Phy Phys BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 4 .;():-. 7 4 0 0 0 0 1
14. Antibiotic 14. 1 14 14. 14. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 . 1 10 0 0 0 0 1
guidelines -recommendations guidelines g gu gui guid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -. 2 8 0 0 0 0 1
Centers for centers C Ce Cen Cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 10 5 .- 2 9 0 0 0 0 1
ted December ted t te ted ted BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 10 5 ,.://../ 8 8 0 0 0 0 1
hicpac/recommendations/antibiotic-stewardship- hicpac/recommendations/antibiotic-stewardship- hicpac/recommendations/antibiotic-stewardship- h hi hic hicp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 //-- 4 10 0 1 0 0 1
statement.html. Accessed statement.html. s st sta stat BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 ... 3 8 0 1 0 0 1
15. Del 15. 1 15 15. 15. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,,,. 5 9 0 0 0 0 1
report from report r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 9 0 0 0 0 1
Dermatology of dermatology D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 8 0 0 0 0 1
Society: Part society: S So Soc Soci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 5 :: 2 10 0 0 0 0 1
tissue infections tissue t ti tis tiss BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -- 2 9 0 0 0 0 1
sistant Staphylococcus sistant s si sis sist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 ,- 2 8 0 0 0 0 1
tered scenarios tered t te ter tere BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 no 0 8 0 0 0 0 1
needed, and needed, n ne nee need BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 , 1 9 0 0 0 0 1
antibiotics in antibiotics a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 .- 2 8 0 0 0 0 1
tol. 2016;9(6):17-24. tol. t to tol tol. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 .;():-. 7 4 0 0 0 0 1
16. Del 16. 1 16 16. 16. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 7 .,,,. 5 9 0 0 0 0 1
report from report r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 no 0 10 0 0 0 0 1
Dermatology of dermatology D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 7 no 0 8 0 0 0 0 1
Society: Part society: S So Soc Soci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 7 ::, 3 9 0 0 0 0 1
sources of sources s so sou sour BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 ,- 2 8 0 0 0 0 1
sumption and sumption s su sum sump BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 7 , 1 9 0 0 0 0 1
impact of impact i im imp impa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 , 1 9 0 0 0 0 1
clinical sequelae clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 . 1 9 0 0 0 0 1
Dermatol. 2016;9(4):18-24. dermatol. D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 7 .;():-. 7 5 0 0 0 0 1
17. Stein 17. 1 17 17. 17. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,,,. 5 10 0 0 0 0 1
and safety and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 -. 2 9 0 0 0 0 1
2%, benzoyl 2%, 2 2% 2%, 2%, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 ,.,. 4 8 0 0 0 0 1
gel for gel g ge gel gel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 --: 3 8 0 0 0 0 1
phase II phase p ph pha phas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 -. 2 9 0 0 0 0 1
Am J am A Am Am Am BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 8 .;():-. 7 6 0 0 0 0 1
18. Stein 18. 1 18 18. 18. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,,,. 5 10 0 0 0 0 1
phosphate 1.2%/adapalene phosphate p ph pho phos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 ././ 4 8 0 0 0 0 1
3.1% gel 3.1% 3 3. 3.1 3.1% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .--: 4 8 0 0 0 0 1
safety results safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 . 1 8 0 0 0 0 1
J Am j J J J J BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 10 8 .;():-. 7 6 0 0 0 0 1
19. Martin 19. 1 19 19. 19. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 .,,,.- 6 10 0 0 0 0 1
related quality related r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 9 no 0 9 0 0 0 0 1
acne-assessment of acne-assessment a ac acn acne BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 9 --- 3 8 0 0 0 0 1
naire. Clin naire. n na nai nair BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 9 ..;():-. 8 8 0 0 0 0 1
20. Dreno 20. 2 20 20. 20. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 10 .,,,.- 6 10 0 0 0 0 1
international study international i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 10 no 0 8 0 0 0 0 1
emerging acne emerging e em eme emer BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 10 :. 2 8 0 0 0 0 1
Acad Dermatol acad A Ac Aca Acad BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 10 .;():-. 7 8 0 0 0 0 1
21. Skroza 21. 2 21 21. 21. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 10 .,,,. 5 9 0 0 0 0 1
versus adolescent versus v ve ver vers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 10 :, 2 10 0 0 0 0 1
patients. J patients. p pa pat pati BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 10 ..;():-. 8 8 0 0 0 0 1
22. ClindagelÒ 22. 2 22 22. 22. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 10 .() 3 9 0 0 0 0 1
[package insert]. [package [ [p [pa [pac BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 10 [].,,;. 7 10 0 0 0 0 1
23. TazoracÒ 23. 2 23 23. 23. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 11 .[].,.,, 8 10 0 0 0 0 1
NJ; 2018. nj; N NJ NJ; NJ; BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 11 ;. 2 1 0 0 0 0 1
24. AltrenoÒ 24. 2 24 24. 24. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 11 .[].- 5 10 0 0 0 0 1
nies, Inc., nies, n ni nie nies BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 11 ,.,,;. 6 6 0 0 0 0 1
25. AkliefÒ 25. 2 25 25. 25. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 11 .[].,. 6 10 0 1 0 0 1
P., Fort p., P P. P., P., BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 11 .,,;. 5 4 0 1 0 0 1
1226 1226 1226 1 12 122 1226 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 10 11 no 0 1 0 1 0 0 0
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 11 ()():- 6 10 0 1 1 0 0
26. AmzeeqÒ 26. 2 26 26. 26. BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .[]., 5 10 0 1 0 0 1
Inc., Bridgewater, inc., I In Inc Inc. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 .,,;. 5 5 0 1 0 0 1
ArazloÒ [package arazloò A Ar Ara Araz BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 [].- 4 10 0 1 0 0 1
nies, Inc., nies, n ni nie nies BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 ,.,,;. 6 7 0 1 0 0 1
28. WinleviÒ 28. 2 28 28. 28. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .[].,.,, 8 10 0 1 0 0 1
Italy; 2020. italy; I It Ita Ital BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 ;. 2 2 0 1 0 0 1
29. DifferinÒ 29. 2 29 29. 29. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .[]., 5 10 0 0 0 0 1
L.P., Fort l.p., L L. L.P L.P. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 ..,,;. 6 5 0 0 0 0 1
30. Huang 30. 3 30 30. 30. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,,,. 5 10 0 0 0 0 1
efficacy of efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 no 0 9 0 0 0 0 1
vulgaris: a vulgaris: v vu vul vulg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 :- 2 9 0 0 0 0 1
controlled trials. controlled c co con cont BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 ..;():-. 8 9 0 0 0 0 1
31. Tan 31. 3 31 31. 31. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 1 .,,.- 5 10 0 0 0 0 1
gists in gists g gi gis gist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 1 . 1 9 0 0 0 0 1
J Cutan j J J J J BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 11 1 .;():-. 7 6 0 0 0 0 1
32. Gold 32. 3 32 32. 32. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 1 .,,-,. 6 10 0 0 0 0 1
American study american A Am Ame Amer BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 1 - 1 8 0 0 0 0 1
combination gel combination c co com comb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 1 .. 2 9 0 0 0 0 1
2009;84(2):110-6. 2009;84(2):110-6. 2009;84(2):110-6. 2 20 200 2009 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 1 ;():-. 6 3 0 0 0 0 1
33. Leyden 33. 3 33 33. 33. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 2 .,,,. 5 10 0 0 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 2 no 0 9 0 0 0 0 1
gel formulation gel g ge gel gel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 2 - 1 8 0 0 0 0 1
damycin with damycin d da dam damy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 2 , 1 8 0 0 0 0 1
vehicle gel vehicle v ve veh vehi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 2 . 1 9 0 0 0 0 1
Clin Dermatol. clin C Cl Cli Clin BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 2 .;():-. 7 5 0 0 0 0 1
34. Pariser 34. 3 34 34. 34. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 3 .,,-,. 6 10 0 0 0 0 1
aqueous gel aqueous a aq aqu aque BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 3 no 0 8 0 0 0 0 1
phosphate 1.2% phosphate p ph pho phos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 .. 2 8 0 0 0 0 1
the once-daily the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 - 1 9 0 0 0 0 1
vulgaris. J vulgaris. v vu vul vulg BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 3 ..;():-. 8 8 0 0 0 0 1
35. Stein 35. 3 35 35. 35. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 3 .,,,. 5 10 0 0 0 0 1
severe inflammatory severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 no 0 9 0 0 0 0 1
with single-agent with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 --- 3 9 0 0 0 0 1
nation adapalene nation n na nat nati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 11 3 ./.: 4 9 0 0 0 0 1
randomized, double-blind, randomized, r ra ran rand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 3 ,-,-, 5 9 0 0 0 0 1
study. Am study. s st stu stud BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 ..;():-. 8 8 0 0 0 0 1
36. Thiboutot 36. 3 36 36. 36. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 4 .,,,. 5 10 0 0 0 0 1
gel fixed gel g ge gel gel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 4 . 1 8 0 0 0 0 1
2% and 2% 2 2% 2% 2% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 4 .- 2 8 0 0 0 0 1
treatment of treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 4 : 1 8 0 0 0 0 1
assessment of assessment a as ass asse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 4 . 1 9 0 0 0 0 1
J Am j J J J J BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 11 4 .;():-. 7 7 0 0 0 0 1
37. Tschen 37. 3 37 37. 37. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,,,. 5 10 0 0 0 0 1
benzoyl peroxide benzoyl b be ben benz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 no 0 8 0 0 0 0 1
compared with compared c co com comp BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 , 1 8 0 0 0 0 1
phosphate, and phosphate, p ph pho phos BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 , 1 10 0 1 0 0 1
vulgaris. Cutis. vulgaris. v vu vul vulg BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 ..;():-. 8 7 0 1 0 0 1
38. Graber 38. 3 38 38. 38. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .. 2 10 0 1 0 0 1
of antibiotics: of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 :..;(): 7 8 0 1 0 0 1
321-30. 321-30. 321-30. 3 32 321 321- BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 -. 2 1 0 1 0 0 1
39. Feldman 39. 3 39 39. 39. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 10 0 0 0 0 1
topical combination topical t to top topi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 : 1 8 0 0 0 0 1
effect size effect e ef eff effe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 . 1 9 0 0 0 0 1
Dermatol. 2024;23(2):42-9. dermatol. D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 6 .;():-. 7 4 0 0 0 0 1
40. Goldberg 40. 4 40 40. 40. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 7 .,,,. 5 10 0 0 0 0 1
age of age a ag age age BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 7 : 1 9 0 0 0 0 1
puberty? Pediatr puberty? p pu pub pube BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 7 ?.;():-. 8 8 0 0 0 0 1
41. Kumtornrut 41. 4 41 41. 41. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 7 .,,,.- 6 9 0 0 0 0 1
gens modulate gens g ge gen gens BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 7 - 1 9 0 0 0 0 1
rectly through rectly r re rec rect BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 7 no 0 9 0 0 0 0 1
from dermal from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 7 ..;(): 6 10 0 0 0 0 1
150-8. 150-8. 150-8. 1 15 150 150- BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 7 -. 2 1 0 0 0 0 1
42. Dre 42. 4 42 42. 42. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 ..: 3 10 0 0 0 0 1
challenge. J challenge. c ch cha chal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 8 .. 2 7 0 0 0 0 1
2015;29(Suppl 5):14-9. 2015;29(suppl 2 20 201 2015 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 8 ;():-. 6 4 0 0 0 0 1
43. Stein 43. 4 43 43. 43. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 .,,,. 5 10 0 0 0 0 1
0.045% lotion 0.045% 0 0. 0.0 0.04 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 .: 2 9 0 0 0 0 1
adult age adult a ad adu adul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 8 ..;(): 6 8 0 0 0 0 1
587-95. 587-95. 587-95. 5 58 587 587- BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 -. 2 1 0 0 0 0 1
44. Anderson 44. 4 44 44. 44. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 9 .,,,. 5 10 0 0 0 0 1
Frequency of frequency F Fr Fre Freq BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 9 - 1 9 0 0 0 0 1
ment. JAMA ment. m me men ment BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 9 ..;():-. 8 7 0 0 0 0 1
45. Dre 45. 4 45 45. 45. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 9 .,,,.- 6 10 0 0 0 0 1
worldwide observational worldwide w wo wor worl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 no 0 8 0 0 0 0 1
acne therapy. acne a ac acn acne BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 ..;():-. 8 8 0 0 0 0 1
46. Kircik 46. 4 46 46. 46. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 9 .,,.- 5 10 0 0 0 0 1
sion technology sion s si sio sion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 9 .- 2 9 0 0 0 0 1
matol. 2019;18(4):s148-54. matol. m ma mat mato BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 9 .;():-. 7 5 0 0 0 0 1
47. Tanghetti 47. 4 47 47. 47. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .,,,.- 6 10 0 0 0 0 1
standing the standing s st sta stan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 10 . 1 9 0 0 0 0 1
Aesthet Dermatol. aesthet A Ae Aes Aest BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 10 .;():-. 7 6 0 0 0 0 1
48. Eichenfield 48. 4 48 48. 48. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .,,.- 5 10 0 0 0 0 1
ment of ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 :.. 3 7 0 0 0 0 1
2021;326(20):2055-67. 2021;326(20):2055-67. 2021;326(20):2055-67. 2 20 202 2021 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 10 ;():-. 6 4 0 0 0 0 1
49. Harper 49. 4 49 49. 49. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 .,,,.- 6 10 0 0 0 0 1
tained acne tained t ta tai tain BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 11 -- 2 9 0 0 0 0 1
damycin phosphate damycin d da dam damy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 11 ././ 4 7 0 0 0 0 1
benzoyl peroxide benzoyl b be ben benz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 11 ... 3 8 0 0 0 0 1
2024;23(3):125-31. 2024;23(3):125-31. 2024;23(3):125-31. 2 20 202 2024 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 11 ;():-. 6 3 0 0 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 ()():- 6 10 0 1 1 0 0
1227 1227 1227 1 12 122 1227 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 11 11 no 0 1 0 1 0 0 0

